



Belgian Cancer Registry

CANCER FACT SHEET 2023

HEAD AND NECK CANCER

ICD-10 C00-C14; C30-C32



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

HPV: Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of some H&N cancers.

H&N cancer is divided in sub-locations according to ICD-10 codes:

- **Lip:** C00
- **Oral cavity:** C02-C05.0; C06

- **Oropharynx:** C01; C05.1-C05.9; C09-C10
- **Nasopharynx:** C11
- **Hypopharynx:** C12-C13
- **Larynx:** C32
- **Nasal cavity and paranasal sinuses:** C30-C31
- **Salivary glands:** C07-C08
- **Other and ill-defined sites:** C14



1. CANCER INCIDENCE	5
1.1. Head & Neck cancer incidence: by region	5
1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Head & Neck cancer incidence: by tumour stage	7
1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	7
1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	9
2. CANCER INCIDENCE TRENDS	12
2.1. Head & Neck cancer incidence trends: by region.....	12
2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	12
2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	13
2.2. Head & Neck cancer incidence trends: by tumour stage	14
2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards...	14
2.3. Head & Neck cancer incidence trends: by age group	15
2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	15
2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	16
3. CANCER PREVALENCE	17
3.1. Head & Neck cancer prevalence: by region.....	17
3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023	17
4. CANCER SURVIVAL.....	18
4.1. Head & Neck cancer survival: by region	18
4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023	18
4.2. Head & Neck cancer survival: by sub-location and tumour stage	20
4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023.....	20
4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2014-2023.....	27
4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2014-2023	34

5. CANCER SURVIVAL TRENDS.....	43
5.1. Head & Neck cancer survival trends: by tumour stage.....	43
5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023	43
6. CANCER MORTALITY	45
6.1. Head & Neck cancer mortality: by region.....	45
6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	45
7. CANCER MORTALITY TRENDS.....	47
7.1. Head & Neck cancer mortality trends: by region	47
7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	47
7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	49

1. CANCER INCIDENCE



1.1. Head & Neck cancer incidence: by region

1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	2	5	3	4	11	13	46	58	124	204	325	376	317	203	109	68	19	6	1,893	33.9
	[0.0]	[0.0]	[0.6]	[1.5]	[0.9]	[1.1]	[2.8]	[3.5]	[12.0]	[15.5]	[31.4]	[50.7]	[86.7]	[118.2]	[119.0]	[99.9]	[87.3]	[85.3]	[60.6]	[99.0]	[32.9]	(32.3; 35.4)
Brussels	0	0	0	1	1	2	2	0	6	11	13	14	30	27	16	18	11	6	3	0	161	38.1
	[0.0]	[0.0]	[0.0]	[2.7]	[2.5]	[3.9]	[3.8]	[0.0]	[13.0]	[25.0]	[31.7]	[39.5]	[104.0]	[126.4]	[95.1]	[142.6]	[136.7]	[119.9]	[130.3]	[0.0]	[26.5]	(32.1; 44.2)
Flanders	0	0	2	3	2	2	7	9	30	28	43	103	173	224	195	122	67	43	9	6	1,068	31.1
	[0.0]	[0.0]	[1.0]	[1.6]	[1.1]	[1.0]	[3.2]	[4.3]	[13.5]	[13.3]	[18.8]	[42.5]	[75.6]	[114.3]	[118.8]	[93.6]	[81.3]	[79.9]	[43.3]	[151.1]	[31.9]	(29.2; 33.0)
Wallonia	0	0	0	1	0	0	2	4	10	19	68	87	122	125	106	63	31	19	7	0	664	38.2
	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[3.4]	[8.6]	[16.1]	[54.3]	[69.7]	[104.3]	[124.0]	[124.1]	[104.5]	[90.1]	[90.8]	[85.1]	[0.0]	[36.9]	(35.3; 41.1)
Females																						
Belgium	0	0	2	1	1	3	4	9	18	26	47	75	98	151	119	93	59	44	22	7	779	12.4
	[0.0]	[0.0]	[0.6]	[0.3]	[0.3]	[0.8]	[1.0]	[2.4]	[4.7]	[7.1]	[12.1]	[18.9]	[25.7]	[44.6]	[40.1]	[37.8]	[33.9]	[32.9]	[31.0]	[33.6]	[13.1]	(11.5; 13.3)
Brussels	0	0	0	1	1	1	0	2	3	3	6	3	7	12	8	10	5	1	1	0	64	12.7
	[0.0]	[0.0]	[0.0]	[2.8]	[2.4]	[1.8]	[0.0]	[4.2]	[6.6]	[7.3]	[15.7]	[8.8]	[23.1]	[48.0]	[37.3]	[55.5]	[38.9]	[10.2]	[17.6]	[0.0]	[10.1]	(9.6; 15.9)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	2	0	0	2	3	4	11	13	27	38	51	81	67	52	39	29	17	4	440	11.6
	[0.0]	[0.0]	[1.0]	[0.0]	[0.0]	[1.0]	[1.4]	[1.9]	[5.0]	[6.3]	[12.0]	[16.1]	[22.3]	[40.1]	[38.2]	[34.6]	[35.6]	[34.0]	[38.6]	[32.6]	[12.9]	(10.5; 12.7)
Wallonia	0	0	0	0	0	0	1	3	4	10	14	34	40	58	44	31	15	14	4	3	275	13.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[2.5]	[3.4]	[8.4]	[11.2]	[26.9]	[32.5]	[52.0]	[44.0]	[40.0]	[28.9]	[36.2]	[18.9]	[46.3]	[14.6]	(12.1; 15.3)

1.2. Head & Neck cancer incidence: by tumour stage

1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	100 [3.0]	238 [24.8]	106 [23.8]	445 [7.7]	8.0 (7.2; 8.7)	45 [1.4]	100 [9.8]	44 [6.8]	189 [3.2]	3.1 (2.6; 3.5)
II	75 [2.2]	139 [14.5]	75 [16.8]	289 [5.0]	5.2 (4.6; 5.8)	38 [1.1]	64 [6.3]	45 [7.0]	148 [2.5]	2.3 (2.0; 2.7)
III	69 [2.0]	170 [17.7]	72 [16.2]	311 [5.4]	5.6 (5.0; 6.2)	29 [0.9]	55 [5.4]	29 [4.5]	113 [1.9]	1.8 (1.5; 2.1)
IV	174 [5.2]	410 [42.7]	120 [26.9]	704 [12.2]	12.5 (11.5; 13.4)	47 [1.4]	121 [11.9]	79 [12.2]	247 [4.2]	3.9 (3.4; 4.4)
X/NA	50 [1.5]	61 [6.4]	32 [7.2]	144 [2.5]	2.6 (2.2; 3.0)	25 [0.8]	28 [2.8]	28 [4.3]	82 [1.4]	1.3 (1.0; 1.6)

1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	75 [2.2]	143 [14.9]	64 [14.4]	283 [4.9]	5.0 (4.5; 5.6)	53 [1.6]	66 [6.5]	35 [5.4]	155 [2.6]	2.6 (2.2; 3.0)
II	39 [1.2]	62 [6.5]	24 [5.4]	125 [2.2]	2.2 (1.8; 2.6)	24 [0.7]	38 [3.7]	33 [5.1]	95 [1.6]	1.5 (1.2; 1.8)
III	24 [0.7]	52 [5.4]	15 [3.4]	91 [1.6]	1.6 (1.3; 1.9)	12 [0.4]	14 [1.4]	8 [1.2]	34 [0.6]	0.5 (0.4; 0.7)
IV	62 [1.8]	143 [14.9]	46 [10.3]	251 [4.4]	4.5 (3.9; 5.0)	10 [0.3]	51 [5.0]	28 [4.3]	89 [1.5]	1.4 (1.1; 1.7)
X/NA	268 [8.0]	618 [64.4]	256 [57.5]	1,143 [19.8]	20.5 (19.3; 21.7)	85 [2.6]	199 [19.6]	121 [18.7]	406 [6.8]	6.4 (5.8; 7.0)

1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	115 [3.4]	254 [26.5]	118 [26.5]	488 [8.5]	8.8 (8.0; 9.5)	60 [1.8]	102 [10.0]	45 [7.0]	208 [3.5]	3.4 (3.0; 3.9)
II	79 [2.3]	131 [13.7]	70 [15.7]	280 [4.9]	5.1 (4.5; 5.7)	35 [1.1]	69 [6.8]	48 [7.4]	152 [2.6]	2.4 (2.0; 2.8)
III	69 [2.0]	163 [17.0]	68 [15.3]	300 [5.2]	5.4 (4.8; 6.0)	29 [0.9]	46 [4.5]	27 [4.2]	102 [1.7]	1.6 (1.3; 2.0)
IV	171 [5.1]	428 [44.6]	127 [28.5]	726 [12.6]	12.8 (11.9; 13.8)	48 [1.4]	133 [13.1]	84 [13.0]	265 [4.5]	4.2 (3.7; 4.7)
X/NA	34 [1.0]	42 [4.4]	22 [4.9]	99 [1.7]	1.8 (1.4; 2.1)	12 [0.4]	18 [1.8]	21 [3.3]	52 [0.9]	0.8 (0.6; 1.0)

1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Lip C00	I	3 [0.1]	7 [0.7]	10 [2.2]	20 [0.3]	0.4 (0.2; 0.5)	3 [0.1]	7 [0.7]	5 [0.8]	15 [0.3]	0.2 (0.1; 0.4)
	II	2 [0.1]	0 [0.0]	6 [1.3]	8 [0.1]	0.2 (0.0; 0.3)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	III	2 [0.1]	1 [0.1]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	X/NA	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
Oral cavity C02-C05.0;C06	I	28 [0.8]	54 [5.6]	19 [4.3]	101 [1.8]	1.8 (1.4; 2.1)	27 [0.8]	33 [3.2]	13 [2.0]	73 [1.2]	1.2 (0.9; 1.5)
	II	19 [0.6]	31 [3.2]	14 [3.1]	64 [1.1]	1.2 (0.9; 1.4)	10 [0.3]	29 [2.9]	27 [4.2]	66 [1.1]	1.0 (0.8; 1.3)
	III	8 [0.2]	36 [3.8]	12 [2.7]	56 [1.0]	1.0 (0.7; 1.3)	8 [0.2]	10 [1.0]	9 [1.4]	27 [0.5]	0.4 (0.3; 0.6)
	IV	61 [1.8]	96 [10.0]	33 [7.4]	190 [3.3]	3.4 (2.9; 3.8)	17 [0.5]	57 [5.6]	42 [6.5]	116 [2.0]	1.8 (1.5; 2.1)
	X/NA	3 [0.1]	3 [0.3]	4 [0.9]	10 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	3 [0.3]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
Pharynx C01;C05.1-C05.9;C09-C13	I	57 [1.7]	98 [10.2]	25 [5.6]	180 [3.1]	3.2 (2.7; 3.6)	9 [0.3]	33 [3.2]	9 [1.4]	51 [0.9]	0.8 (0.6; 1.1)
	II	39 [1.2]	53 [5.5]	22 [4.9]	114 [2.0]	2.0 (1.7; 2.4)	11 [0.3]	21 [2.1]	7 [1.1]	39 [0.7]	0.6 (0.4; 0.8)
	III	41 [1.2]	82 [8.5]	32 [7.2]	155 [2.7]	2.8 (2.3; 3.2)	12 [0.4]	24 [2.4]	9 [1.4]	45 [0.8]	0.7 (0.5; 0.9)
	IV	80 [2.4]	223 [23.2]	49 [11.0]	352 [6.1]	6.2 (5.5; 6.8)	23 [0.7]	54 [5.3]	22 [3.4]	99 [1.7]	1.6 (1.3; 1.9)
	X/NA	12 [0.4]	19 [2.0]	9 [2.0]	40 [0.7]	0.7 (0.5; 1.0)	2 [0.1]	7 [0.7]	6 [0.9]	15 [0.3]	0.2 (0.1; 0.4)
Oropharynx C01;C05.1-C05.9;C09-C10	I	52 [1.5]	81 [8.4]	21 [4.7]	154 [2.7]	2.7 (2.3; 3.1)	8 [0.2]	32 [3.1]	8 [1.2]	48 [0.8]	0.8 (0.6; 1.0)
	II	26 [0.8]	41 [4.3]	20 [4.5]	87 [1.5]	1.5 (1.2; 1.9)	8 [0.2]	17 [1.7]	4 [0.6]	29 [0.5]	0.5 (0.3; 0.6)
	III	24 [0.7]	55 [5.7]	21 [4.7]	100 [1.7]	1.8 (1.4; 2.1)	6 [0.2]	21 [2.1]	6 [0.9]	33 [0.6]	0.5 (0.3; 0.7)
	IV	42 [1.2]	125 [13.0]	18 [4.0]	185 [3.2]	3.2 (2.7; 3.7)	13 [0.4]	41 [4.0]	11 [1.7]	65 [1.1]	1.1 (0.8; 1.3)
	X/NA	9 [0.3]	16 [1.7]	9 [2.0]	34 [0.6]	0.6 (0.4; 0.8)	2 [0.1]	6 [0.6]	6 [0.9]	14 [0.2]	0.2 (0.1; 0.3)
Nasopharynx C11	I	3 [0.1]	0 [0.0]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)

locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
	II	9 [0.3]	6 [0.6]	1 [0.2]	16 [0.3]	0.3 (0.1; 0.4)	2 [0.1]	0 [0.0]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	III	11 [0.3]	3 [0.3]	5 [1.1]	19 [0.3]	0.3 (0.2; 0.5)	6 [0.2]	0 [0.0]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
	IV	13 [0.4]	5 [0.5]	3 [0.7]	21 [0.4]	0.4 (0.2; 0.5)	6 [0.2]	1 [0.1]	0 [0.0]	7 [0.1]	0.1 (0.0; 0.2)
	X/NA	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
Hypopharynx C12-C13	I	2 [0.1]	17 [1.8]	4 [0.9]	23 [0.4]	0.4 (0.2; 0.6)	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)
	II	4 [0.1]	6 [0.6]	1 [0.2]	11 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	4 [0.4]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	III	6 [0.2]	24 [2.5]	6 [1.3]	36 [0.6]	0.6 (0.4; 0.9)	0 [0.0]	3 [0.3]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	IV	25 [0.7]	93 [9.7]	28 [6.3]	146 [2.5]	2.6 (2.2; 3.0)	4 [0.1]	12 [1.2]	11 [1.7]	27 [0.5]	0.4 (0.3; 0.6)
	X/NA	2 [0.1]	3 [0.3]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Larynx C32	I	17 [0.5]	83 [8.7]	56 [12.6]	156 [2.7]	2.9 (2.4; 3.3)	6 [0.2]	15 [1.5]	14 [2.2]	35 [0.6]	0.6 (0.4; 0.7)
	II	11 [0.3]	36 [3.8]	21 [4.7]	68 [1.2]	1.3 (1.0; 1.6)	1 [0.0]	11 [1.1]	4 [0.6]	16 [0.3]	0.3 (0.1; 0.4)
	III	10 [0.3]	35 [3.6]	16 [3.6]	61 [1.1]	1.1 (0.8; 1.4)	6 [0.2]	11 [1.1]	4 [0.6]	21 [0.4]	0.3 (0.2; 0.5)
	IV	21 [0.6]	75 [7.8]	22 [4.9]	118 [2.0]	2.1 (1.7; 2.5)	5 [0.2]	12 [1.2]	7 [1.1]	24 [0.4]	0.4 (0.2; 0.5)
	X/NA	2 [0.1]	4 [0.4]	2 [0.4]	8 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	0 [0.0]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
Nasal cavity and paranasal sinuses C30-C31	I	4 [0.1]	8 [0.8]	5 [1.1]	17 [0.3]	0.3 (0.2; 0.5)	3 [0.1]	4 [0.4]	3 [0.5]	10 [0.2]	0.2 (0.1; 0.3)
	II	1 [0.0]	6 [0.6]	5 [1.1]	12 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	3 [0.3]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	III	2 [0.1]	6 [0.6]	3 [0.7]	11 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
	IV	8 [0.2]	21 [2.2]	9 [2.0]	38 [0.7]	0.7 (0.5; 0.9)	2 [0.1]	4 [0.4]	6 [0.9]	12 [0.2]	0.2 (0.1; 0.3)
	X/NA	11 [0.3]	11 [1.1]	3 [0.7]	26 [0.5]	0.5 (0.3; 0.6)	3 [0.1]	5 [0.5]	4 [0.6]	13 [0.2]	0.2 (0.1; 0.3)
Salivary glands C07-C08	I	6 [0.2]	4 [0.4]	3 [0.7]	14 [0.2]	0.3 (0.1; 0.4)	12 [0.4]	10 [1.0]	1 [0.2]	24 [0.4]	0.4 (0.2; 0.6)
	II	7 [0.2]	5 [0.5]	2 [0.4]	14 [0.2]	0.2 (0.1; 0.4)	11 [0.3]	4 [0.4]	6 [0.9]	21 [0.4]	0.3 (0.2; 0.5)
	III	6 [0.2]	3 [0.3]	4 [0.9]	13 [0.2]	0.2 (0.1; 0.4)	3 [0.1]	0 [0.0]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.2)
	IV	1 [0.0]	13 [1.4]	14 [3.1]	28 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	6 [0.6]	6 [0.9]	13 [0.2]	0.2 (0.1; 0.3)

locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
	X/NA	3 [0.1]	2 [0.2]	2 [0.4]	7 [0.1]	0.1 (0.0; 0.2)	3 [0.1]	2 [0.2]	3 [0.5]	8 [0.1]	0.1 (0.0; 0.2)
Other and ill-defined sites C14	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	X/NA	3 [0.1]	3 [0.3]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)

2. CANCER INCIDENCE TRENDS



2.1. Head & Neck cancer incidence trends: by region

2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	1,953	1,856	1,780	1,982	1,954	1,969	1,838	2,027	1,968	1,996	2,019	1,965	2,018	2,011	1,985	2,073	1,833	1,951	1,933	1,893		
CR	38.4	36.3	34.6	38.3	37.4	37.4	34.6	37.7	36.4	36.6	36.9	35.7	36.4	36.1	35.5	36.8	32.4	34.4	33.9	32.9		
ESR2013	44.6	41.9	39.3	43.1	42.0	42.1	38.7	42.0	40.1	40.0	40.2	38.6	39.0	38.4	37.7	38.7	33.9	35.7	34.9	33.9	-1.1 (-1.4; -0.8)	2004-2023
Brussels N	167	161	173	200	163	160	159	177	156	167	170	170	175	154	141	160	132	152	153	161		
CR	34.8	33.3	35.3	40.3	32.3	31.0	30.2	32.6	28.2	29.7	30.0	29.7	30.2	26.4	24.0	27.0	22.1	25.4	25.5	26.5		
ESR2013	46.1	45.0	48.6	55.4	45.2	44.2	42.9	47.8	41.4	42.6	44.7	43.7	43.9	39.6	34.3	39.5	32.3	37.8	35.6	38.1	-1.7 (-2.3; -1.1)	2004-2023
Flanders N	1,062	969	973	1,017	1,022	1,055	1,004	1,080	1,058	1,122	1,111	1,074	1,084	1,110	1,118	1,178	1,048	1,093	1,105	1,068		
CR	35.8	32.5	32.5	33.7	33.6	34.4	32.5	34.7	33.7	35.6	35.1	33.7	33.9	34.5	34.5	36.1	31.9	33.2	33.3	31.9		
ESR2013	40.8	36.5	35.7	36.8	36.4	37.6	35.0	37.3	35.7	37.0	36.4	34.5	34.4	34.5	34.8	36.0	31.8	32.7	32.5	31.1	-0.9 (-1.2; -0.6)	2004-2023
Wallonia N	724	726	634	765	769	754	675	770	754	707	738	721	759	747	726	735	653	706	675	664		
CR	44.1	44.1	38.3	45.9	45.8	44.7	39.7	44.9	43.7	40.8	42.4	41.2	43.2	42.3	41.0	41.4	36.6	39.6	37.7	36.9		
ESR2013	51.5	51.5	43.2	51.9	52.1	50.2	44.8	49.5	48.1	45.0	46.2	45.0	46.5	45.8	43.9	43.7	38.2	41.2	39.4	38.2	-1.4 (-1.8; -0.9)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	557	560	533	548	587	637	616	667	693	652	687	739	698	704	760	711	710	840	778	779	1.0 (0.6; 1.4)	2004-2023
CR	10.5	10.5	9.9	10.1	10.8	11.6	11.1	12.0	12.3	11.5	12.1	13.0	12.2	12.2	13.2	12.3	12.2	14.4	13.2	13.1		
ESR2013	10.9	10.9	10.4	10.4	11.0	12.0	11.4	12.1	12.5	11.6	12.2	12.9	12.0	12.0	12.8	11.9	11.8	13.8	12.7	12.4		
Brussels N	62	67	71	51	57	66	66	70	73	54	55	73	61	69	79	60	51	64	60	64	-0.8 (-1.8; 0.3)	2004-2023
CR	11.9	12.8	13.4	9.5	10.5	12.0	11.7	12.1	12.5	9.1	9.2	12.1	10.0	11.3	12.9	9.7	8.2	10.3	9.6	10.1		
ESR2013	13.6	14.8	16.1	11.4	12.6	14.6	14.3	14.5	15.5	10.9	11.5	14.6	12.1	14.1	16.2	11.8	10.4	12.7	12.1	12.7		
Flanders N	268	286	249	270	289	307	310	335	358	365	346	388	369	354	410	394	399	430	434	440	1.6 (1.1; 2.0)	2004-2023
CR	8.8	9.3	8.1	8.7	9.3	9.8	9.8	10.5	11.1	11.3	10.7	11.9	11.3	10.7	12.4	11.8	11.9	12.8	12.8	12.9		
ESR2013	9.0	9.6	8.2	8.7	9.1	9.8	9.8	10.3	10.8	11.0	10.3	11.4	10.7	10.0	11.5	11.0	11.1	11.8	11.8	11.6		
Wallonia N	227	207	213	227	241	264	240	262	262	233	286	278	268	281	271	257	260	346	284	275	0.6 (-0.1; 1.2)	2004-2023
CR	13.0	11.8	12.1	12.8	13.6	14.8	13.3	14.5	14.4	12.7	15.6	15.1	14.5	15.2	14.6	13.8	14.0	18.6	15.2	14.6		
ESR2013	13.6	12.5	12.7	13.3	14.1	15.3	13.5	14.8	14.8	13.0	15.7	15.1	14.3	15.2	14.2	13.4	13.5	17.8	14.6	13.7		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Head & Neck cancer incidence trends: by tumour stage

2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	490	428	488	450	488	1.9 (1.1; 2.7) 2004-2023	210	198	239	205	208	5.4 (4.5; 6.2) 2004-2023 10.3 (7.0; 13.6) 2004-2010 3.2 (1.9; 4.4) 2011-2023	
	CR	8.7	7.6	8.6	7.9	8.5		3.6	3.4	4.1	3.5	3.5		
	ESR2013	9.2	8.0	9.0	8.1	8.8		3.5	3.3	4.0	3.4	3.4		
II	N	291	255	300	311	280	1.0 (0.3; 1.6) 2004-2023	113	104	127	133	152	3.2 (2.5; 3.9) 2004-2023	
	CR	5.2	4.5	5.3	5.4	4.9		1.9	1.8	2.2	2.3	2.6		
	ESR2013	5.5	4.7	5.5	5.7	5.1		1.9	1.7	2.1	2.2	2.4		
III	N	297	318	302	325	300	0.3 (-0.3; 0.9) 2004-2023	100	110	141	120	102	2.7 (1.6; 3.7) 2004-2023	
	CR	5.3	5.6	5.3	5.7	5.2		1.7	1.9	2.4	2.0	1.7		
	ESR2013	5.6	5.9	5.5	5.9	5.4		1.6	1.8	2.3	2.0	1.6		
IV	N	837	743	723	738	726	-0.2 (-0.6; 0.1) 2004-2023 2.1 (1.3; 2.9) 2004-2014 -2.8 (-3.7; -1.9) 2015-2023	237	239	277	279	265	2.0 (1.4; 2.7) 2004-2023 5.0 (3.6; 6.4) 2004-2014 -1.1 (-2.6; 0.4) 2015-2023	
	CR	14.9	13.1	12.7	12.9	12.6		4.1	4.1	4.7	4.7	4.5		
	ESR2013	15.5	13.7	13.2	13.3	12.8		3.9	3.9	4.5	4.5	4.2		
X/NA	N	158	89	138	109	99	-10.5 (-11.5; -9.4) 2004-2023	51	59	56	41	52	-8.9 (-9.7; -8.2) 2004-2023	
	CR	2.8	1.6	2.4	1.9	1.7		0.9	1.0	1.0	0.7	0.9		
	ESR2013	3.0	1.7	2.5	2.0	1.8		0.9	1.0	0.9	0.7	0.8		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Head & Neck cancer incidence trends: by age group

2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59	N	953	880	834	897	856	847	742	816	802	780	716	701	688	656	625	633	530	546	493	468		
	CR	29.8	27.4	25.9	27.7	26.3	25.9	22.6	24.7	24.2	23.5	21.5	21.1	20.6	19.7	18.7	19.0	15.9	16.3	14.7	13.9		
	ESR2013	31.8	29.0	26.9	28.8	27.3	26.7	23.2	25.2	24.4	23.6	21.4	20.8	20.3	19.2	18.3	18.4	15.4	15.9	14.3	13.7	-4.0 (-4.3; -3.7)	2004-2023
																						-2.9 (-3.7; -2.1)	2004-2013
																						-5.0 (-5.6; -4.3)	2014-2023
60-74	N	722	706	685	809	795	796	765	896	865	895	958	922	1,002	1,016	1,012	1,045	932	1,024	1,023	1,018		
	CR	106.1	103.1	99.7	115.6	111.6	109.5	103.2	118.5	112.4	114.2	120.2	113.4	120.3	118.6	115.1	116.3	101.6	109.6	108.2	106.1		
	ESR2013	106.4	103.2	99.7	114.9	110.3	109.8	103.0	118.2	111.8	113.2	118.6	112.9	120.5	118.3	115.3	116.3	101.9	109.9	108.2	107.0	0.1 (-0.3; 0.4)	2004-2023
																						1.1 (0.5; 1.7)	2004-2016
																						-1.6 (-2.7; -0.6)	2017-2023
75+	N	275	269	259	274	302	324	328	312	299	320	342	338	324	337	347	393	371	380	416	405		
	CR	93.8	88.9	82.5	84.1	89.7	93.8	92.6	86.4	81.0	85.1	89.2	86.3	82.1	85.4	87.4	97.3	89.7	91.3	96.5	91.0		
	ESR2013	92.8	87.8	78.1	80.9	87.4	92.7	89.8	85.6	81.7	83.9	88.7	86.2	80.1	84.0	88.1	96.5	89.9	91.4	96.4	90.4	0.4 (-0.1; 0.8)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59 N	245	236	240	254	257	275	257	262	270	232	250	249	197	214	217	206	199	237	214	184		
CR	7.8	7.5	7.6	8.0	8.0	8.5	7.9	8.0	8.3	7.1	7.6	7.6	6.0	6.5	6.6	6.3	6.1	7.2	6.5	5.5		
ESR2013	8.1	7.8	7.8	8.2	8.2	8.7	8.1	8.1	8.3	7.1	7.5	7.5	5.9	6.3	6.4	6.1	5.9	7.1	6.4	5.5	-1.5 (-2.3; -0.8)	2004-2023
																					2.9 (-2.2; 8.4)	2004-2007
																					-2.3 (-3.1; -1.6)	2008-2023
60-74 N	187	197	186	177	196	237	223	250	284	271	294	325	325	310	342	322	325	391	366	368		
CR	24.1	25.4	24.1	22.7	24.9	29.6	27.5	30.4	34.0	32.0	34.3	37.3	36.4	33.8	36.4	33.6	33.3	39.3	36.4	36.2		
ESR2013	24.1	25.6	24.4	22.7	24.8	29.7	27.5	30.3	33.8	31.9	34.1	37.2	36.4	33.8	36.3	33.6	33.2	39.4	36.5	36.3	2.4 (1.9; 3.0)	2004-2023
																					4.0 (3.0; 5.0)	2004-2015
																					0.3 (-1.1; 1.7)	2016-2023
75+ N	124	127	104	114	133	122	134	152	138	147	142	163	174	180	199	182	183	210	197	225		
CR	23.9	23.9	19.1	20.5	23.3	21.1	22.8	25.6	23.0	24.3	23.3	26.4	28.2	29.4	32.6	29.6	29.5	33.9	31.1	34.9		
ESR2013	24.3	23.9	19.1	20.2	23.5	21.4	23.2	25.5	22.8	24.1	23.6	26.1	28.2	29.7	33.6	30.4	30.9	34.9	32.4	35.2	2.5 (1.8; 3.3)	2004-2023
																					0.0 (-2.8; 2.8)	2004-2010
																					3.4 (-0.2; 7.1)	2011-2014
																					3.9 (2.2; 5.6)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Head & Neck cancer prevalence: by region

3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	1,628	6,161	9,584	11,636	12,815	674	2,590	4,090	5,065	5,628
	CR	28.1	106.3	165.3	201	221	11.3	43.4	68.6	85	94
	ESR2013	28.7	108.6	169.5	206.4	227.9	10.7	41.2	64.8	80.1	88.9
Brussels	N	133	454	728	901	989	56	209	361	458	506
	CR	21.7	74.2	118.9	147.2	161.5	8.8	32.8	56.6	71.9	79.4
	ESR2013	31.0	105.8	173.1	217.6	240.9	10.9	40.8	70.5	89.2	98.2
Flanders	N	933	3,592	5,610	6,837	7,553	389	1,453	2,272	2,785	3,086
	CR	27.6	106.4	166.1	202.4	223.6	11.3	42.2	66.0	80.9	89.6
	ESR2013	26.7	102.8	160.8	196.2	217.0	10.2	38.4	59.7	73.1	80.9
Wallonia	N	562	2,115	3,246	3,898	4,273	229	928	1,457	1,822	2,036
	CR	31.1	117.0	179.6	215.7	236.4	12.1	49.2	77.3	96.7	108.0
	ESR2013	31.8	119.8	184.8	223.0	245.5	11.4	46.4	72.4	90.4	100.8

4. CANCER SURVIVAL



4.1. Head & Neck cancer survival: by region

4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		25,791	80.2% (79.7%; 80.7%)	64.2% (63.5%; 64.9%)	56.4% (55.7%; 57.2%)	43.2% (41.3%; 45.3%)
Males						
Belgium	All ages	18,715	80.0% (79.4%; 80.6%)	62.9% (62.1%; 63.7%)	54.8% (53.9%; 55.8%)	41.4% (39.5%; 43.5%)
	15-59	5,800	85.2% (84.2%; 86.1%)	67.3% (66.1%; 68.6%)	58.8% (57.4%; 60.2%)	47.3% (45.5%; 49.3%)
	60-74	9,477	79.3% (78.4%; 80.1%)	62.2% (61.1%; 63.3%)	53.3% (52.1%; 54.6%)	38.3% (36.4%; 40.3%)
	75+	3,553	73.6% (71.9%; 75.3%)	57.6% (55.4%; 59.9%)	52.0% (49.1%; 55.2%)	39.3% (31.0%; 49.9%)
Brussels	All ages	1,499	77.1% (74.8%; 79.3%)	60.9% (58.1%; 63.8%)	53.4% (50.3%; 56.8%)	43.1% (37.7%; 49.4%)
	15-59	528	84.1% (80.9%; 87.3%)	66.8% (62.7%; 71.2%)	61.1% (56.6%; 65.9%)	51.1% (45.2%; 57.9%)
	60-74	687	74.5% (71.2%; 77.9%)	57.5% (53.6%; 61.6%)	47.1% (42.8%; 51.7%)	29.5% (23.3%; 37.3%)
	75+	290	70.7% (64.9%; 76.9%)	58.4% (51.0%; 66.8%)	54.6% (45.2%; 66.0%)	64.5% (44.6%; 93.1%)
Flanders	All ages	10,479	81.7% (80.9%; 82.5%)	66.1% (65.0%; 67.2%)	58.5% (57.2%; 59.8%)	45.8% (42.8%; 49.0%)
	15-59	2,930	87.0% (85.8%; 88.2%)	71.6% (69.9%; 73.4%)	63.8% (61.9%; 65.8%)	53.4% (50.7%; 56.1%)
	60-74	5,348	81.1% (80.0%; 82.2%)	64.7% (63.2%; 66.1%)	56.6% (55.0%; 58.3%)	43.9% (41.2%; 46.7%)
	75+	2,270	76.3% (74.2%; 78.4%)	61.9% (59.1%; 64.8%)	55.6% (51.8%; 59.8%)	39.3% (28.7%; 53.8%)
Wallonia	All ages	6,740	78.0% (77.0%; 79.1%)	58.5% (57.2%; 59.8%)	49.4% (48.0%; 50.9%)	34.3% (32.1%; 36.8%)

Net Survival Probability, 2014-2023							
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	15-59	2,342	83.1% (81.6%; 84.7%)	62.0% (60.0%; 64.1%)	52.1% (50.0%; 54.4%)	39.3% (36.5%; 42.3%)	
	60-74	3,444	77.4% (76.0%; 78.9%)	59.2% (57.5%; 61.0%)	49.5% (47.5%; 51.5%)	31.5% (28.6%; 34.7%)	
	75+	994	68.2% (65.1%; 71.5%)	47.3% (43.5%; 51.5%)	43.0% (38.3%; 48.2%)	31.9% (22.2%; 45.9%)	
Females							
Belgium	All ages	7,076	80.6% (79.7%; 81.6%)	67.6% (66.4%; 68.9%)	60.8% (59.3%; 62.2%)	48.3% (43.7%; 53.4%)	
	15-59	2,089	89.5% (88.2%; 90.8%)	78.4% (76.6%; 80.3%)	71.7% (69.6%; 73.9%)	60.1% (57.0%; 63.5%)	
	60-74	3,230	81.8% (80.5%; 83.2%)	66.7% (65.0%; 68.5%)	58.7% (56.8%; 60.8%)	44.9% (41.9%; 48.2%)	
	75+	1,799	68.4% (66.0%; 70.8%)	56.6% (53.7%; 59.7%)	51.3% (47.6%; 55.3%)	39.3% (25.2%; 61.3%)	
Brussels	All ages	622	80.0% (76.8%; 83.4%)	67.5% (63.5%; 71.8%)	60.4% (55.7%; 65.4%)	42.2% (35.0%; 50.9%)	
	15-59	212	93.5% (90.2%; 97.0%)	84.3% (79.4%; 89.6%)	80.3% (74.6%; 86.4%)	68.7% (58.4%; 80.8%)	
	60-74	259	79.7% (74.8%; 84.9%)	63.7% (57.8%; 70.4%)	57.0% (50.5%; 64.4%)	41.6% (32.7%; 53.0%)	
	75+	153	62.5% (54.7%; 71.4%)	50.2% (41.2%; 61.0%)	37.2% (26.9%; 51.5%)	FU<10y	
Flanders	All ages	3,786	82.3% (81.0%; 83.6%)	70.3% (68.6%; 72.0%)	63.2% (61.2%; 65.3%)	54.8% (50.2%; 59.9%)	
	15-59	1,031	90.8% (89.1%; 92.6%)	81.3% (78.9%; 83.9%)	74.7% (71.8%; 77.7%)	66.1% (62.0%; 70.5%)	
	60-74	1,701	84.1% (82.3%; 86.0%)	69.9% (67.5%; 72.3%)	62.2% (59.5%; 65.0%)	50.3% (45.9%; 55.1%)	
	75+	1,080	71.3% (68.3%; 74.5%)	60.2% (56.4%; 64.3%)	53.5% (48.7%; 58.8%)	50.4% (36.9%; 68.7%)	
Wallonia	All ages	2,668	78.4% (76.8%; 80.1%)	63.9% (61.9%; 65.9%)	57.4% (55.1%; 59.7%)	40.9% (32.6%; 51.4%)	
	15-59	846	86.8% (84.6%; 89.2%)	73.4% (70.3%; 76.5%)	66.0% (62.6%; 69.5%)	50.5% (45.5%; 56.0%)	
	60-74	1,270	79.2% (76.9%; 81.5%)	63.1% (60.4%; 66.0%)	54.6% (51.5%; 57.8%)	38.9% (34.6%; 43.6%)	
	75+	566	64.3% (60.1%; 68.8%)	51.6% (46.7%; 57.1%)	50.6% (44.6%; 57.6%)	31.1% (12.3%; 78.1%)	

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2. Head & Neck cancer survival: by sub-location and tumour stage

4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,791	80.2% (79.7%; 80.7%)	70.3% (69.7%; 70.9%)	64.2% (63.5%; 64.9%)	59.9% (59.2%; 60.7%)	56.4% (55.7%; 57.2%)	43.2% (41.3%; 45.3%)
Males								
Head & Neck (C00-C14, C30-C32)	All	18,715	80.0% (79.4%; 80.6%)	69.6% (68.9%; 70.3%)	62.9% (62.1%; 63.7%)	58.5% (57.6%; 59.3%)	54.8% (53.9%; 55.8%)	41.4% (39.5%; 43.5%)
	I	3,613	95.8% (94.9%; 96.7%)	91.1% (89.8%; 92.3%)	86.8% (85.3%; 88.4%)	83.6% (81.7%; 85.6%)	80.7% (78.5%; 83.0%)	63.7% (56.0%; 72.4%)
	II	2,655	90.6% (89.3%; 91.8%)	82.5% (80.9%; 84.3%)	75.2% (73.2%; 77.2%)	70.7% (68.5%; 72.9%)	66.6% (64.2%; 69.1%)	53.5% (48.5%; 59.0%)
	III	2,883	81.8% (80.3%; 83.3%)	71.9% (70.1%; 73.7%)	65.4% (63.4%; 67.5%)	60.9% (58.7%; 63.1%)	56.9% (54.5%; 59.4%)	38.7% (34.5%; 43.4%)
	IV	7,501	68.1% (67.0%; 69.2%)	53.2% (52.0%; 54.4%)	44.9% (43.7%; 46.2%)	40.0% (38.7%; 41.3%)	35.6% (34.3%; 36.9%)	24.7% (22.9%; 26.7%)
	X/NA	2,706	78.9% (77.3%; 80.6%)	68.7% (66.8%; 70.7%)	62.8% (60.8%; 65.0%)	57.8% (55.6%; 60.1%)	55.6% (53.2%; 58.0%)	43.4% (39.5%; 47.8%)
Lip (C00)	All	326	94.2% (90.7%; 97.7%)	90.1% (85.4%; 95.1%)	87.2% (81.5%; 93.3%)	86.9% (80.2%; 94.1%)	86.8% (79.2%; 95.2%)	89.5% (61.3%; 130.8%)
	I	145	97.8% (93.5%; 102.3%)	96.6% (90.3%; 103.2%)	93.8% (85.6%; 102.7%)	96.1% (87.0%; 106.1%)	92.3% (81.1%; 105.0%)	63.2% (27.0%; 148.3%)
	II	34	N<50	N<50	N<50	N<50	N<50	N<50
	III	18	N<50	N<50	N<50	N<50	N<50	N<50
	IV	19	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	110	96.6% (91.3%; 102.2%)	94.5% (87.2%; 102.5%)	91.6% (82.5%; 101.8%)	86.6% (74.8%; 100.2%)	88.3% (75.4%; 103.5%)	119.4% (95.2%; 149.6%)
Oral cavity (C02-C05.0, C06)	All	4,314	80.5% (79.2%; 81.7%)	69.6% (68.2%; 71.1%)	62.4% (60.8%; 64.0%)	57.3% (55.6%; 59.1%)	53.2% (51.4%; 55.2%)	40.1% (36.7%; 43.8%)
	I	810	95.2% (93.4%; 97.0%)	88.2% (85.5%; 90.9%)	82.8% (79.6%; 86.1%)	77.4% (73.7%; 81.4%)	73.4% (69.2%; 77.9%)	62.4% (55.9%; 69.7%)
	II	681	91.0% (88.6%; 93.5%)	82.3% (79.0%; 85.6%)	72.9% (69.0%; 76.9%)	67.9% (63.6%; 72.4%)	62.4% (57.8%; 67.5%)	52.0% (44.1%; 61.2%)
	III	638	80.7% (77.5%; 84.0%)	70.4% (66.7%; 74.3%)	62.6% (58.5%; 67.0%)	56.4% (52.0%; 61.2%)	52.4% (47.6%; 57.8%)	37.8% (28.8%; 49.5%)

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	1,665	68.8% (66.5%; 71.1%)	54.4% (51.9%; 57.0%)	46.4% (43.9%; 49.1%)	41.4% (38.7%; 44.1%)	37.0% (34.3%; 40.0%)	26.4% (22.2%; 31.3%)
	X/NA	588	81.4% (78.1%; 84.9%)	71.6% (67.7%; 75.8%)	66.0% (61.8%; 70.6%)	61.3% (56.7%; 66.3%)	58.4% (53.6%; 63.7%)	38.5% (30.0%; 49.5%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,085	75.2% (74.2%; 76.2%)	62.7% (61.6%; 63.8%)	55.1% (53.9%; 56.3%)	50.3% (49.1%; 51.6%)	46.1% (44.8%; 47.4%)	32.8% (30.8%; 35.0%)
	I	976	93.0% (91.2%; 94.9%)	84.7% (82.2%; 87.4%)	79.3% (76.3%; 82.5%)	74.5% (71.1%; 78.2%)	71.3% (67.4%; 75.5%)	47.9% (39.1%; 58.6%)
	II	1,004	88.2% (86.1%; 90.5%)	79.3% (76.5%; 82.2%)	71.3% (68.0%; 74.6%)	66.7% (63.1%; 70.4%)	61.6% (57.7%; 65.7%)	45.7% (38.5%; 54.1%)
	III	1,333	81.0% (78.8%; 83.2%)	70.5% (67.9%; 73.2%)	64.9% (62.1%; 67.8%)	61.0% (57.9%; 64.2%)	57.3% (54.0%; 60.7%)	42.0% (36.9%; 47.8%)
	IV	4,167	67.0% (65.6%; 68.5%)	51.8% (50.3%; 53.4%)	43.0% (41.4%; 44.7%)	38.5% (36.9%; 40.2%)	34.1% (32.4%; 35.8%)	24.3% (22.0%; 26.8%)
	X/NA	771	69.4% (66.1%; 72.8%)	56.6% (53.1%; 60.4%)	49.6% (46.0%; 53.5%)	42.9% (39.2%; 46.9%)	39.9% (36.1%; 44.0%)	25.8% (21.3%; 31.2%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	5,386	77.7% (76.5%; 78.8%)	65.7% (64.3%; 67.0%)	58.7% (57.2%; 60.1%)	54.1% (52.5%; 55.6%)	49.8% (48.2%; 51.4%)	36.2% (33.6%; 39.0%)
	I	831	93.5% (91.6%; 95.5%)	85.9% (83.1%; 88.7%)	81.5% (78.2%; 84.8%)	76.9% (73.1%; 80.8%)	74.3% (70.1%; 78.8%)	52.0% (41.9%; 64.7%)
	II	740	90.3% (88.0%; 92.8%)	82.1% (78.9%; 85.3%)	73.7% (69.9%; 77.6%)	68.4% (64.3%; 72.7%)	63.9% (59.5%; 68.8%)	49.7% (41.5%; 59.5%)
	III	857	80.3% (77.5%; 83.2%)	70.1% (66.9%; 73.5%)	65.0% (61.5%; 68.7%)	61.7% (58.0%; 65.6%)	56.5% (52.5%; 60.8%)	41.1% (34.6%; 48.9%)
	IV	2,426	68.8% (66.9%; 70.7%)	53.7% (51.7%; 55.9%)	45.8% (43.7%; 47.9%)	41.7% (39.6%; 44.0%)	37.2% (35.0%; 39.5%)	27.7% (24.7%; 31.1%)
	X/NA	583	71.9% (68.2%; 75.8%)	59.1% (55.0%; 63.4%)	51.7% (47.5%; 56.3%)	44.6% (40.3%; 49.3%)	42.2% (37.9%; 47.1%)	26.4% (21.3%; 32.8%)
Nasopharynx C11	All	465	85.0% (81.7%; 88.5%)	77.5% (73.6%; 81.7%)	72.2% (67.9%; 76.9%)	69.8% (65.2%; 74.8%)	67.3% (62.4%; 72.6%)	60.3% (53.3%; 68.1%)
	I	30	N<50	N<50	N<50	N<50	N<50	N<50
	II	86	92.0% (86.0%; 98.5%)	87.7% (79.8%; 96.4%)	86.9% (78.2%; 96.4%)	85.8% (76.6%; 96.2%)	87.0% (77.6%; 97.5%)	78.8% (61.2%; 101.5%)
	III	145	90.6% (85.7%; 95.8%)	87.9% (82.3%; 93.9%)	82.6% (75.9%; 89.9%)	79.9% (72.6%; 87.9%)	80.8% (73.4%; 88.9%)	77.7% (68.0%; 88.8%)
	IV	168	77.5% (71.3%; 84.2%)	68.6% (61.7%; 76.3%)	59.9% (52.4%; 68.4%)	56.3% (48.5%; 65.2%)	50.8% (42.7%; 60.5%)	42.0% (31.6%; 55.7%)
	X/NA	36	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	All	2,381	67.4% (65.5%; 69.4%)	52.3% (50.2%; 54.4%)	42.7% (40.6%; 44.9%)	37.2% (35.1%; 39.5%)	32.8% (30.6%; 35.1%)	19.3% (16.4%; 22.7%)
	I	118	89.3% (83.4%; 95.7%)	77.4% (69.4%; 86.4%)	63.8% (54.5%; 74.8%)	56.1% (46.3%; 67.9%)	50.7% (40.7%; 63.3%)	25.2% (13.1%; 48.5%)
	II	181	77.5% (71.2%; 84.2%)	63.3% (56.1%; 71.4%)	53.1% (45.5%; 61.9%)	49.7% (41.9%; 59.1%)	39.6% (31.5%; 49.7%)	18.0% (8.6%; 37.8%)
	III	333	78.4% (73.8%; 83.2%)	63.9% (58.7%; 69.7%)	56.7% (51.0%; 63.1%)	50.9% (44.5%; 58.1%)	49.1% (42.5%; 56.6%)	28.4% (20.3%; 39.6%)
	IV	1,594	63.2% (60.8%; 65.6%)	47.0% (44.5%; 49.6%)	36.9% (34.4%; 39.6%)	31.7% (29.2%; 34.3%)	27.3% (24.9%; 30.0%)	16.6% (13.4%; 20.5%)
	X/NA	158	59.9% (52.6%; 68.2%)	49.2% (41.7%; 57.9%)	42.5% (35.1%; 51.4%)	35.9% (28.7%; 44.9%)	31.4% (24.4%; 40.5%)	21.5% (13.2%; 34.8%)
Larynx (C32)	All	4,673	85.6% (84.5%; 86.7%)	78.5% (77.1%; 79.9%)	73.1% (71.5%; 74.7%)	68.6% (66.8%; 70.4%)	65.2% (63.3%; 67.2%)	48.2% (43.4%; 53.6%)
	I	1,548	97.4% (96.2%; 98.7%)	95.7% (93.9%; 97.4%)	92.2% (90.0%; 94.6%)	89.6% (86.5%; 92.7%)	87.2% (83.7%; 90.9%)	70.0% (57.9%; 84.5%)
	II	732	90.8% (88.3%; 93.2%)	83.1% (79.9%; 86.4%)	77.3% (73.6%; 81.3%)	72.2% (68.1%; 76.7%)	68.4% (63.8%; 73.4%)	56.4% (48.2%; 66.1%)
	III	717	82.1% (79.1%; 85.3%)	72.9% (69.3%; 76.6%)	66.8% (62.9%; 71.0%)	61.2% (56.9%; 65.8%)	57.2% (52.6%; 62.1%)	37.3% (29.6%; 47.1%)
	IV	1,143	70.2% (67.5%; 73.0%)	56.9% (53.9%; 60.1%)	49.6% (46.5%; 52.9%)	43.6% (40.4%; 47.1%)	39.1% (35.7%; 42.7%)	20.2% (15.6%; 26.1%)
	X/NA	533	81.8% (78.3%; 85.4%)	76.1% (72.0%; 80.4%)	70.2% (65.6%; 75.2%)	65.6% (60.5%; 71.0%)	62.9% (57.5%; 68.9%)	45.1% (36.4%; 55.8%)
Nasal cavity and paranasal sinuses (C30-C31)	All	987	82.3% (79.7%; 84.9%)	70.2% (67.1%; 73.6%)	64.3% (60.7%; 68.0%)	60.5% (56.7%; 64.6%)	60.2% (56.2%; 64.5%)	48.0% (39.4%; 58.5%)
	I	101	97.1% (92.6%; 102.0%)	88.1% (80.2%; 96.7%)	81.5% (71.8%; 92.7%)	80.6% (70.1%; 92.6%)	82.8% (72.1%; 95.2%)	67.9% (46.4%; 99.3%)
	II	115	99.7% (95.8%; 103.7%)	96.7% (90.5%; 103.3%)	92.0% (83.4%; 101.5%)	88.5% (77.8%; 100.7%)	90.8% (79.1%; 104.2%)	62.1% (30.0%; 128.7%)
	III	103	86.9% (79.7%; 94.7%)	80.1% (71.2%; 90.0%)	68.7% (58.1%; 81.4%)	65.9% (54.5%; 79.7%)	66.8% (54.8%; 81.6%)	18.6% (5.2%; 66.5%)
	IV	330	68.2% (63.1%; 73.7%)	51.7% (46.2%; 57.9%)	45.2% (39.5%; 51.8%)	42.1% (36.3%; 48.9%)	40.0% (34.0%; 47.2%)	31.7% (23.2%; 43.4%)
	X/NA	340	84.3% (80.1%; 88.7%)	71.3% (66.0%; 77.0%)	67.1% (61.3%; 73.5%)	61.9% (55.6%; 68.8%)	60.9% (54.3%; 68.3%)	57.4% (45.8%; 71.8%)
Salivary glands (C07-C08)	All	762	87.1% (84.4%; 89.9%)	76.1% (72.5%; 79.8%)	70.4% (66.4%; 74.7%)	68.1% (63.6%; 72.8%)	63.5% (57.9%; 69.6%)	57.1% (48.6%; 67.2%)
	I	75	100.6% (96.8%; 104.6%)	100.4% (94.2%; 107.0%)	104.5% (97.3%; 112.2%)	110.7% (102.3%; 119.7%)	101.4% (81.2%; 126.5%)	93.7% (58.7%; 149.6%)
	II	111	96.3% (91.6%; 101.3%)	92.9% (86.4%; 99.9%)	88.7% (80.6%; 97.6%)	89.9% (81.0%; 99.7%)	89.2% (78.8%; 101.0%)	78.4% (60.0%; 102.4%)

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	89	90.3% (82.9%; 98.4%)	82.2% (72.2%; 93.5%)	75.7% (63.1%; 90.9%)	74.6% (60.6%; 91.8%)	60.4% (40.4%; 90.3%)	29.5% (13.3%; 65.3%)
	IV	213	69.4% (63.0%; 76.5%)	51.1% (44.1%; 59.3%)	44.5% (37.1%; 53.3%)	34.2% (26.6%; 43.9%)	27.8% (20.1%; 38.5%)	24.8% (14.4%; 42.9%)
	X/NA	274	92.5% (88.7%; 96.4%)	80.1% (74.6%; 85.9%)	72.1% (65.9%; 79.0%)	70.7% (64.1%; 78.0%)	69.4% (62.4%; 77.2%)	69.0% (57.9%; 82.2%)
Other and ill-defined sites (C14)	All	138	53.5% (45.6%; 62.7%)	42.8% (35.0%; 52.3%)	38.0% (30.3%; 47.5%)	31.6% (24.2%; 41.1%)	30.1% (22.7%; 39.9%)	13.6% (6.4%; 28.9%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	137	53.1% (45.3%; 62.4%)	42.3% (34.6%; 51.8%)	37.4% (29.8%; 47.0%)	31.0% (23.6%; 40.5%)	29.4% (22.1%; 39.2%)	13.9% (6.6%; 29.4%)
Females								
Head & Neck (C00-C14, C30-C32)	All	7,076	80.6% (79.7%; 81.6%)	72.3% (71.1%; 73.4%)	67.6% (66.4%; 68.9%)	63.8% (62.5%; 65.2%)	60.8% (59.3%; 62.2%)	48.3% (43.7%; 53.4%)
	I	1,464	95.7% (94.5%; 97.0%)	93.2% (91.5%; 94.9%)	90.1% (88.0%; 92.2%)	86.7% (84.2%; 89.3%)	85.8% (82.9%; 88.7%)	78.1% (68.7%; 88.8%)
	II	1,111	91.7% (89.8%; 93.6%)	85.5% (83.0%; 87.9%)	81.1% (78.3%; 84.1%)	76.6% (73.3%; 80.1%)	73.7% (70.0%; 77.7%)	50.8% (31.4%; 82.0%)
	III	1,020	81.9% (79.4%; 84.4%)	72.2% (69.3%; 75.3%)	66.3% (63.1%; 69.6%)	62.3% (58.8%; 66.0%)	58.2% (54.5%; 62.2%)	50.4% (42.5%; 59.7%)
	IV	2,447	64.7% (62.8%; 66.7%)	51.8% (49.8%; 53.9%)	46.0% (43.9%; 48.2%)	42.4% (40.2%; 44.6%)	38.5% (36.2%; 40.8%)	27.3% (23.4%; 31.8%)
	X/NA	1,254	82.5% (80.3%; 84.9%)	75.1% (72.4%; 77.8%)	70.9% (68.0%; 73.9%)	66.1% (62.9%; 69.4%)	63.4% (60.1%; 66.9%)	49.8% (44.5%; 55.6%)
Lip (C00)	All	166	94.9% (90.2%; 99.9%)	88.6% (81.8%; 96.1%)	85.5% (77.1%; 94.9%)	82.2% (72.1%; 93.7%)	81.2% (69.5%; 94.9%)	76.3% (52.3%; 111.5%)
	I	68	99.6% (94.5%; 104.9%)	102.2% (95.2%; 109.6%)	95.9% (84.2%; 109.2%)	92.2% (78.2%; 108.6%)	98.1% (83.3%; 115.6%)	77.6% (39.6%; 152.2%)
	II	26	N<50	N<50	N<50	N<50	N<50	N<50
	III	9	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	54	97.0% (88.8%; 105.9%)	85.6% (72.8%; 100.7%)	85.2% (70.4%; 103.2%)	76.0% (58.1%; 99.4%)	72.4% (52.6%; 99.7%)	69.3% (40.7%; 118.0%)

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oral cavity (C02-C05.0, C06)	All	2,499	80.5% (78.9%; 82.2%)	70.7% (68.8%; 72.7%)	66.3% (64.2%; 68.5%)	62.5% (60.2%; 64.9%)	59.8% (57.3%; 62.4%)	49.3% (39.6%; 61.2%)
	I	554	96.5% (94.6%; 98.5%)	92.8% (90.0%; 95.6%)	90.3% (86.9%; 93.8%)	86.8% (82.7%; 91.1%)	83.5% (78.9%; 88.5%)	80.0% (71.4%; 89.7%)
	II	418	90.5% (87.3%; 93.9%)	85.8% (81.8%; 90.1%)	80.0% (74.9%; 85.4%)	75.7% (69.6%; 82.2%)	72.9% (66.1%; 80.4%)	37.4% (13.6%; 103.2%)
	III	315	84.6% (80.4%; 89.0%)	70.6% (65.3%; 76.3%)	65.5% (59.7%; 71.8%)	59.3% (52.9%; 66.4%)	58.7% (52.1%; 66.2%)	61.6% (50.4%; 75.3%)
	IV	855	62.6% (59.3%; 66.1%)	47.7% (44.3%; 51.4%)	43.3% (39.8%; 47.1%)	40.5% (36.9%; 44.4%)	36.7% (33.0%; 40.9%)	26.7% (19.0%; 37.4%)
	X/NA	404	83.3% (79.4%; 87.4%)	74.0% (69.3%; 79.0%)	68.4% (63.3%; 74.0%)	64.6% (59.2%; 70.5%)	62.8% (57.0%; 69.1%)	55.7% (47.0%; 65.9%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,688	77.0% (75.3%; 78.6%)	67.4% (65.5%; 69.2%)	61.9% (60.0%; 64.0%)	57.3% (55.2%; 59.4%)	53.6% (51.4%; 55.9%)	40.0% (36.1%; 44.2%)
	I	411	91.9% (89.0%; 94.8%)	88.2% (84.7%; 91.8%)	82.8% (78.6%; 87.3%)	77.8% (72.9%; 83.0%)	76.0% (70.6%; 81.8%)	53.3% (32.0%; 88.9%)
	II	414	91.1% (88.1%; 94.1%)	82.9% (79.0%; 87.0%)	79.7% (75.3%; 84.2%)	73.4% (68.4%; 78.7%)	70.2% (64.9%; 76.0%)	56.7% (48.2%; 66.8%)
	III	460	79.3% (75.6%; 83.3%)	70.6% (66.3%; 75.2%)	64.4% (59.8%; 69.3%)	60.5% (55.6%; 65.8%)	56.3% (51.2%; 62.1%)	44.4% (36.3%; 54.2%)
	IV	1,155	65.8% (63.1%; 68.6%)	53.2% (50.3%; 56.3%)	46.0% (43.1%; 49.2%)	42.0% (39.0%; 45.2%)	37.8% (34.7%; 41.1%)	29.1% (25.4%; 33.5%)
	X/NA	293	76.3% (71.4%; 81.6%)	67.0% (61.6%; 72.9%)	65.0% (59.4%; 71.2%)	57.9% (51.9%; 64.6%)	55.2% (49.0%; 62.1%)	34.1% (26.0%; 44.8%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	2,059	78.8% (77.0%; 80.7%)	68.8% (66.7%; 70.9%)	64.1% (61.9%; 66.4%)	60.0% (57.6%; 62.4%)	56.6% (54.2%; 59.3%)	41.3% (36.7%; 46.5%)
	I	357	92.8% (89.8%; 95.8%)	88.3% (84.5%; 92.2%)	83.6% (79.1%; 88.4%)	79.4% (74.3%; 85.0%)	77.7% (72.0%; 83.9%)	53.6% (30.7%; 93.4%)
	II	313	91.4% (88.1%; 94.9%)	82.7% (78.2%; 87.4%)	79.2% (74.2%; 84.6%)	73.1% (67.4%; 79.3%)	70.5% (64.4%; 77.2%)	51.8% (41.6%; 64.4%)
	III	331	80.1% (75.7%; 84.8%)	71.1% (66.1%; 76.5%)	67.0% (61.7%; 72.8%)	63.8% (58.2%; 70.0%)	59.4% (53.3%; 66.2%)	46.5% (36.5%; 59.2%)
	IV	831	68.1% (64.9%; 71.4%)	54.7% (51.3%; 58.3%)	47.7% (44.3%; 51.4%)	44.0% (40.5%; 47.8%)	40.1% (36.6%; 44.1%)	31.1% (26.7%; 36.3%)
	X/NA	248	77.0% (71.8%; 82.7%)	67.6% (61.7%; 74.0%)	66.8% (60.8%; 73.4%)	62.3% (55.9%; 69.5%)	60.5% (53.9%; 67.9%)	37.3% (28.1%; 49.7%)
Nasopharynx C11	All	190	85.2% (80.2%; 90.6%)	81.4% (75.8%; 87.5%)	77.7% (71.6%; 84.4%)	73.3% (66.4%; 80.8%)	72.0% (64.8%; 79.9%)	68.0% (59.1%; 78.2%)

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	11	N<50	N<50	N<50	N<50	N<50	N<50
	II	48	N<50	N<50	N<50	N<50	N<50	N<50
	III	53	85.0% (75.6%; 95.5%)	79.4% (68.9%; 91.5%)	77.4% (66.5%; 90.1%)	74.9% (63.3%; 88.7%)	71.8% (59.2%; 87.0%)	73.9% (61.0%; 89.6%)
	IV	63	73.4% (63.1%; 85.4%)	69.0% (58.2%; 81.7%)	67.5% (56.4%; 80.7%)	68.1% (57.0%; 81.4%)	65.9% (54.1%; 80.1%)	55.4% (39.8%; 77.2%)
	X/NA	15	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	All	469	65.4% (61.1%; 69.9%)	55.3% (50.8%; 60.2%)	45.8% (41.2%; 50.9%)	37.4% (32.7%; 42.7%)	30.7% (26.1%; 36.1%)	21.8% (16.5%; 28.9%)
	I	44	N<50	N<50	N<50	N<50	N<50	N<50
	II	55	82.8% (72.9%; 94.1%)	70.1% (58.3%; 84.2%)	68.9% (56.8%; 83.6%)	61.8% (48.9%; 78.1%)	52.5% (38.8%; 71.2%)	49.1% (33.1%; 72.9%)
	III	76	72.1% (62.5%; 83.1%)	62.5% (52.3%; 74.8%)	45.0% (34.7%; 58.4%)	37.3% (27.1%; 51.3%)	33.6% (23.3%; 48.4%)	18.0% (8.2%; 39.7%)
	IV	264	56.7% (51.0%; 63.1%)	45.0% (39.1%; 51.7%)	35.7% (30.0%; 42.5%)	29.0% (23.4%; 35.9%)	22.5% (17.2%; 29.5%)	15.8% (10.3%; 24.1%)
	X/NA	30	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	All	875	84.8% (82.3%; 87.3%)	77.7% (74.7%; 80.8%)	71.7% (68.3%; 75.2%)	67.5% (63.8%; 71.4%)	64.6% (60.6%; 68.7%)	50.6% (43.5%; 58.8%)
	I	270	96.7% (93.9%; 99.6%)	95.1% (91.4%; 99.0%)	93.3% (88.7%; 98.1%)	91.2% (85.7%; 97.2%)	93.8% (88.0%; 100.1%)	89.9% (73.9%; 109.4%)
	II	142	89.2% (83.9%; 94.8%)	79.3% (72.5%; 86.8%)	71.8% (64.1%; 80.5%)	66.0% (57.6%; 75.6%)	61.1% (52.2%; 71.6%)	45.8% (33.4%; 62.7%)
	III	153	80.4% (73.9%; 87.5%)	72.3% (65.0%; 80.4%)	64.0% (56.0%; 73.2%)	61.9% (53.5%; 71.7%)	51.8% (42.4%; 63.4%)	38.6% (24.2%; 61.7%)
	IV	212	70.0% (63.9%; 76.6%)	56.8% (50.3%; 64.1%)	49.8% (43.1%; 57.6%)	44.9% (38.0%; 53.0%)	43.1% (36.1%; 51.5%)	16.3% (7.9%; 33.8%)
	X/NA	98	84.1% (76.8%; 92.0%)	80.4% (72.2%; 89.5%)	71.0% (61.7%; 81.7%)	62.7% (52.3%; 75.2%)	55.9% (45.3%; 69.1%)	40.5% (28.7%; 57.2%)
Nasal cavity and paranasal sinuses (C30-C31)	All	383	79.9% (75.7%; 84.3%)	72.3% (67.4%; 77.5%)	68.4% (63.2%; 74.0%)	65.4% (59.8%; 71.4%)	63.1% (57.1%; 69.7%)	52.4% (42.0%; 65.4%)
	I	55	96.1% (90.3%; 102.3%)	97.9% (92.0%; 104.3%)	96.8% (88.8%; 105.6%)	93.1% (82.6%; 104.8%)	94.9% (84.3%; 106.9%)	FU<10y
	II	28	N<50	N<50	N<50	N<50	N<50	N<50
	III	32	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	113	57.3% (48.6%; 67.5%)	47.7% (38.7%; 58.7%)	41.3% (32.4%; 52.6%)	35.7% (26.9%; 47.5%)	35.2% (26.1%; 47.4%)	15.5% (6.2%; 38.7%)
	X/NA	155	84.5% (78.5%; 90.9%)	74.7% (67.4%; 82.7%)	72.4% (64.7%; 81.0%)	69.8% (61.6%; 79.1%)	65.3% (56.3%; 75.7%)	43.8% (31.5%; 60.8%)
Salivary glands (C07-C08)	All	593	90.0% (87.2%; 92.8%)	88.1% (84.9%; 91.4%)	87.1% (83.5%; 90.9%)	85.3% (81.0%; 89.9%)	83.2% (78.3%; 88.4%)	66.0% (52.5%; 82.9%)
	I	120	100.5% (98.9%; 102.2%)	98.9% (95.3%; 102.7%)	98.3% (93.5%; 103.2%)	97.5% (91.3%; 104.0%)	97.6% (89.4%; 106.5%)	74.6% (32.8%; 169.5%)
	II	94	100.3% (97.3%; 103.5%)	102.0% (98.1%; 106.0%)	102.5% (96.9%; 108.5%)	103.9% (96.8%; 111.5%)	108.2% (99.9%; 117.2%)	86.5% (58.8%; 127.4%)
	III	54	87.5% (78.1%; 98.0%)	87.8% (77.6%; 99.4%)	87.5% (75.8%; 101.0%)	86.3% (72.6%; 102.5%)	75.4% (59.9%; 94.9%)	52.9% (24.5%; 114.0%)
	IV	113	68.2% (59.6%; 78.0%)	59.4% (50.1%; 70.5%)	59.9% (50.1%; 71.7%)	56.8% (46.1%; 69.8%)	50.2% (38.8%; 64.9%)	37.5% (24.5%; 57.6%)
	X/NA	213	91.7% (87.5%; 96.2%)	91.4% (86.6%; 96.5%)	88.6% (82.8%; 94.8%)	85.9% (78.8%; 93.6%)	84.9% (77.4%; 93.2%)	71.1% (55.7%; 90.6%)
Other and ill-defined sites (C14)	All	46	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	46	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation. Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,791	80.2% (79.7%; 80.7%)	70.3% (69.7%; 70.9%)	64.2% (63.5%; 64.9%)	59.9% (59.2%; 60.7%)	56.4% (55.7%; 57.2%)	43.2% (41.3%; 45.3%)
Males								
Head & Neck (C00-C14, C30-C32)	All	18,715	80.0% (79.4%; 80.6%)	69.6% (68.9%; 70.3%)	62.9% (62.1%; 63.7%)	58.5% (57.6%; 59.3%)	54.8% (53.9%; 55.8%)	41.4% (39.5%; 43.5%)
	I	2,644	97.8% (96.9%; 98.6%)	94.1% (92.8%; 95.4%)	90.1% (88.4%; 91.8%)	86.3% (84.2%; 88.4%)	83.5% (81.1%; 86.1%)	68.0% (61.4%; 75.4%)
	II	1,170	93.8% (92.2%; 95.5%)	86.2% (83.9%; 88.6%)	78.9% (76.0%; 81.9%)	74.9% (71.6%; 78.3%)	70.3% (66.7%; 74.2%)	58.5% (51.4%; 66.6%)
	III	1,097	89.4% (87.4%; 91.5%)	79.4% (76.8%; 82.2%)	73.2% (70.1%; 76.3%)	69.2% (65.9%; 72.7%)	64.9% (61.2%; 68.8%)	52.4% (45.8%; 59.8%)
	IV	2,543	80.7% (79.1%; 82.4%)	63.4% (61.4%; 65.5%)	54.8% (52.7%; 57.0%)	47.7% (45.5%; 50.0%)	42.8% (40.5%; 45.3%)	29.9% (26.3%; 34.1%)
	X/NA	11,751	73.7% (72.8%; 74.5%)	62.6% (61.6%; 63.5%)	55.6% (54.6%; 56.7%)	51.3% (50.2%; 52.4%)	47.7% (46.6%; 48.9%)	34.5% (32.2%; 37.0%)
Lip (C00)	All	326	94.2% (90.7%; 97.7%)	90.1% (85.4%; 95.1%)	87.2% (81.5%; 93.3%)	86.9% (80.2%; 94.1%)	86.8% (79.2%; 95.2%)	89.5% (61.3%; 130.8%)
	I	189	99.8% (96.4%; 103.3%)	98.7% (93.4%; 104.3%)	98.1% (91.3%; 105.4%)	98.4% (90.0%; 107.7%)	98.7% (88.5%; 110.0%)	99.1% (55.7%; 176.1%)
	II	55	96.1% (88.9%; 103.9%)	93.3% (83.7%; 104.1%)	86.6% (74.2%; 101.1%)	90.1% (77.2%; 105.2%)	91.8% (77.8%; 108.4%)	107.3% (83.4%; 138.1%)
	III	19	N<50	N<50	N<50	N<50	N<50	N<50
	IV	12	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	51	79.9% (68.6%; 93.0%)	73.3% (60.4%; 88.9%)	68.3% (53.7%; 86.7%)	64.9% (49.2%; 85.7%)	62.3% (46.1%; 84.1%)	59.3% (40.7%; 86.2%)
Oral cavity (C02-C05.0, C06)	All	4,314	80.5% (79.2%; 81.7%)	69.6% (68.2%; 71.1%)	62.4% (60.8%; 64.0%)	57.3% (55.6%; 59.1%)	53.2% (51.4%; 55.2%)	40.1% (36.7%; 43.8%)
	I	968	98.1% (96.8%; 99.4%)	93.6% (91.6%; 95.7%)	89.0% (86.4%; 91.7%)	84.5% (81.3%; 87.8%)	80.5% (76.7%; 84.5%)	59.9% (51.9%; 69.1%)
	II	588	92.6% (90.1%; 95.0%)	86.5% (83.3%; 89.9%)	78.5% (74.5%; 82.7%)	71.9% (67.3%; 76.9%)	65.5% (60.3%; 71.1%)	54.9% (46.1%; 65.4%)
	III	532	88.1% (85.1%; 91.1%)	77.7% (73.8%; 81.7%)	70.0% (65.7%; 74.6%)	64.8% (60.1%; 69.9%)	60.7% (55.5%; 66.4%)	48.3% (39.2%; 59.5%)
	IV	1,075	80.5% (78.0%; 83.0%)	64.1% (61.1%; 67.2%)	54.5% (51.3%; 57.9%)	47.1% (43.8%; 50.7%)	42.6% (39.1%; 46.3%)	31.8% (25.7%; 39.3%)

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	1,205	57.4% (54.6%; 60.4%)	43.2% (40.4%; 46.3%)	36.4% (33.6%; 39.5%)	33.2% (30.4%; 36.4%)	30.6% (27.7%; 33.8%)	20.5% (16.2%; 25.8%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,085	75.2% (74.2%; 76.2%)	62.7% (61.6%; 63.8%)	55.1% (53.9%; 56.3%)	50.3% (49.1%; 51.6%)	46.1% (44.8%; 47.4%)	32.8% (30.8%; 35.0%)
	I	586	95.0% (93.0%; 97.1%)	87.1% (84.0%; 90.3%)	80.4% (76.6%; 84.4%)	73.6% (69.3%; 78.2%)	71.5% (66.7%; 76.5%)	53.9% (44.9%; 64.6%)
	II	247	91.9% (88.2%; 95.8%)	79.3% (73.9%; 85.1%)	71.8% (65.7%; 78.5%)	67.6% (60.9%; 75.0%)	62.0% (54.8%; 70.2%)	51.1% (39.8%; 65.5%)
	III	216	89.1% (84.7%; 93.7%)	77.6% (71.8%; 83.9%)	73.7% (67.3%; 80.6%)	68.6% (61.7%; 76.2%)	60.7% (53.2%; 69.3%)	56.5% (46.5%; 68.5%)
	IV	633	77.4% (74.1%; 80.9%)	56.4% (52.5%; 60.6%)	48.3% (44.3%; 52.7%)	44.0% (39.9%; 48.5%)	38.2% (34.0%; 42.9%)	27.5% (22.3%; 33.9%)
	X/NA	6,496	72.3% (71.1%; 73.4%)	59.9% (58.7%; 61.2%)	52.1% (50.8%; 53.4%)	47.4% (46.0%; 48.8%)	43.3% (41.8%; 44.8%)	29.9% (27.8%; 32.3%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	5,386	77.7% (76.5%; 78.8%)	65.7% (64.3%; 67.0%)	58.7% (57.2%; 60.1%)	54.1% (52.5%; 55.6%)	49.8% (48.2%; 51.4%)	36.2% (33.6%; 39.0%)
	I	530	95.2% (93.1%; 97.4%)	87.9% (84.7%; 91.2%)	81.6% (77.7%; 85.7%)	75.1% (70.6%; 79.9%)	73.6% (68.7%; 78.9%)	55.8% (46.6%; 66.8%)
	II	207	92.0% (87.9%; 96.2%)	78.6% (72.6%; 85.0%)	72.7% (66.1%; 80.1%)	69.4% (62.2%; 77.5%)	64.8% (57.0%; 73.7%)	53.9% (41.3%; 70.4%)
	III	174	91.8% (87.4%; 96.4%)	82.6% (76.7%; 89.1%)	78.1% (71.4%; 85.5%)	74.5% (67.2%; 82.6%)	65.9% (57.7%; 75.2%)	61.6% (50.8%; 74.8%)
	IV	327	79.6% (75.2%; 84.3%)	62.4% (57.1%; 68.2%)	55.7% (50.2%; 61.8%)	51.8% (46.1%; 58.2%)	46.1% (40.2%; 52.9%)	35.6% (28.3%; 44.7%)
	X/NA	4,190	74.1% (72.7%; 75.5%)	61.9% (60.3%; 63.4%)	54.5% (52.9%; 56.2%)	49.9% (48.2%; 51.7%)	45.6% (43.8%; 47.5%)	31.5% (28.6%; 34.7%)
Nasopharynx C11	All	465	85.0% (81.7%; 88.5%)	77.5% (73.6%; 81.7%)	72.2% (67.9%; 76.9%)	69.8% (65.2%; 74.8%)	67.3% (62.4%; 72.6%)	60.3% (53.3%; 68.1%)
	I	5	N<50	N<50	N<50	N<50	N<50	N<50
	II	3	N<50	N<50	N<50	N<50	N<50	N<50
	III	1	N<50	N<50	N<50	N<50	N<50	N<50
	IV	6	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	450	85.6% (82.3%; 89.0%)	78.1% (74.1%; 82.3%)	72.5% (68.1%; 77.3%)	70.0% (65.3%; 75.0%)	67.3% (62.4%; 72.7%)	59.5% (52.5%; 67.5%)

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	All	2,381	67.4% (65.5%; 69.4%)	52.3% (50.2%; 54.4%)	42.7% (40.6%; 44.9%)	37.2% (35.1%; 39.5%)	32.8% (30.6%; 35.1%)	19.3% (16.4%; 22.7%)
	I	56	94.9% (88.3%; 102.0%)	79.5% (68.5%; 92.2%)	69.2% (56.4%; 84.9%)	59.8% (46.0%; 77.7%)	50.6% (36.3%; 70.5%)	34.5% (14.9%; 79.7%)
	II	37	N<50	N<50	N<50	N<50	N<50	N<50
	III	42	N<50	N<50	N<50	N<50	N<50	N<50
	IV	302	75.8% (70.9%; 81.0%)	50.3% (44.7%; 56.5%)	40.5% (35.0%; 46.9%)	35.4% (29.9%; 42.0%)	29.3% (23.9%; 36.1%)	15.0% (8.5%; 26.5%)
	X/NA	1,944	64.7% (62.5%; 66.9%)	51.1% (48.9%; 53.5%)	41.6% (39.2%; 44.0%)	36.4% (34.0%; 38.9%)	32.5% (30.1%; 35.0%)	19.3% (16.3%; 23.0%)
Larynx (C32)	All	4,673	85.6% (84.5%; 86.7%)	78.5% (77.1%; 79.9%)	73.1% (71.5%; 74.7%)	68.6% (66.8%; 70.4%)	65.2% (63.3%; 67.2%)	48.2% (43.4%; 53.6%)
	I	748	98.9% (97.4%; 100.5%)	97.8% (95.5%; 100.0%)	95.1% (92.0%; 98.3%)	91.8% (87.7%; 96.1%)	89.6% (84.8%; 94.7%)	73.9% (63.3%; 86.3%)
	II	91	91.8% (85.3%; 98.7%)	81.9% (72.9%; 92.0%)	71.7% (61.2%; 84.0%)	69.5% (58.1%; 83.2%)	69.2% (56.9%; 84.1%)	55.0% (30.8%; 98.4%)
	III	177	88.2% (83.2%; 93.5%)	83.0% (77.0%; 89.4%)	76.3% (69.4%; 83.9%)	72.2% (64.5%; 80.8%)	69.1% (60.8%; 78.6%)	52.3% (39.6%; 69.0%)
	IV	521	83.8% (80.5%; 87.3%)	68.3% (64.1%; 72.8%)	60.1% (55.5%; 65.0%)	51.9% (47.1%; 57.2%)	47.3% (42.2%; 53.0%)	28.6% (21.8%; 37.5%)
	X/NA	3,136	82.4% (80.9%; 83.9%)	75.2% (73.5%; 77.0%)	69.8% (67.9%; 71.8%)	65.6% (63.4%; 67.8%)	62.1% (59.7%; 64.5%)	45.0% (39.1%; 51.9%)
Nasal cavity and paranasal sinuses (C30-C31)	All	987	82.3% (79.7%; 84.9%)	70.2% (67.1%; 73.6%)	64.3% (60.7%; 68.0%)	60.5% (56.7%; 64.6%)	60.2% (56.2%; 64.5%)	48.0% (39.4%; 58.5%)
	I	94	95.2% (89.9%; 100.8%)	93.6% (86.9%; 100.9%)	88.7% (79.5%; 98.9%)	83.6% (72.9%; 95.9%)	87.2% (76.0%; 100.0%)	81.7% (58.3%; 114.4%)
	II	83	100.9% (97.5%; 104.4%)	94.0% (86.7%; 102.1%)	87.4% (77.6%; 98.4%)	89.0% (77.8%; 101.8%)	89.0% (76.5%; 103.6%)	55.2% (31.3%; 97.3%)
	III	72	91.8% (84.6%; 99.6%)	81.4% (71.4%; 92.9%)	79.9% (68.3%; 93.5%)	80.7% (68.5%; 95.0%)	83.6% (70.9%; 98.5%)	58.8% (32.6%; 106.2%)
	IV	156	76.2% (69.3%; 83.7%)	61.8% (53.9%; 70.8%)	58.1% (49.8%; 67.8%)	50.5% (41.5%; 61.5%)	46.2% (36.9%; 57.9%)	21.8% (10.2%; 46.8%)
	X/NA	585	78.1% (74.5%; 81.8%)	64.2% (60.0%; 68.7%)	57.1% (52.5%; 62.1%)	53.4% (48.6%; 58.8%)	52.9% (47.8%; 58.5%)	47.2% (36.8%; 60.6%)
Salivary glands (C07-C08)	All	762	87.1% (84.4%; 89.9%)	76.1% (72.5%; 79.8%)	70.4% (66.4%; 74.7%)	68.1% (63.6%; 72.8%)	63.5% (57.9%; 69.6%)	57.1% (48.6%; 67.2%)
	I	108	101.3% (99.4%; 103.1%)	100.4% (96.3%; 104.6%)	99.6% (94.0%; 105.6%)	102.3% (96.1%; 108.8%)	92.7% (79.5%; 108.1%)	88.1% (70.8%; 109.7%)
	II	111	100.3% (97.1%; 103.5%)	93.9% (87.4%; 100.9%)	92.8% (85.2%; 101.0%)	92.7% (83.9%; 102.5%)	91.8% (81.3%; 103.7%)	73.0% (49.2%; 108.5%)

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	85	99.0% (93.8%; 104.4%)	85.5% (75.9%; 96.3%)	77.7% (65.9%; 91.6%)	82.2% (69.4%; 97.4%)	78.9% (64.4%; 96.7%)	64.2% (39.7%; 103.7%)
	IV	156	90.4% (85.1%; 96.1%)	73.1% (65.4%; 81.8%)	62.7% (53.9%; 72.9%)	49.2% (39.8%; 60.8%)	45.1% (34.9%; 58.3%)	44.3% (30.3%; 64.7%)
	X/NA	302	72.2% (66.8%; 78.0%)	59.6% (53.6%; 66.2%)	53.5% (47.0%; 60.8%)	51.7% (44.8%; 59.6%)	47.2% (38.7%; 57.5%)	45.4% (34.1%; 60.3%)
Other and ill-defined sites (C14)	All	138	53.5% (45.6%; 62.7%)	42.8% (35.0%; 52.3%)	38.0% (30.3%; 47.5%)	31.6% (24.2%; 41.1%)	30.1% (22.7%; 39.9%)	13.6% (6.4%; 28.9%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	137	53.1% (45.3%; 62.4%)	42.3% (34.6%; 51.8%)	37.4% (29.8%; 47.0%)	31.0% (23.6%; 40.5%)	29.4% (22.1%; 39.2%)	13.9% (6.6%; 29.4%)
Females								
Head & Neck (C00-C14, C30-C32)	All	7,076	80.6% (79.7%; 81.6%)	72.3% (71.1%; 73.4%)	67.6% (66.4%; 68.9%)	63.8% (62.5%; 65.2%)	60.8% (59.3%; 62.2%)	48.3% (43.7%; 53.4%)
	I	1,382	97.1% (96.0%; 98.3%)	95.3% (93.8%; 96.9%)	92.5% (90.5%; 94.5%)	90.0% (87.6%; 92.5%)	88.4% (85.7%; 91.3%)	77.5% (68.9%; 87.1%)
	II	629	97.6% (95.8%; 99.4%)	91.8% (89.0%; 94.7%)	87.1% (83.4%; 91.0%)	84.3% (79.9%; 88.9%)	80.9% (75.7%; 86.4%)	67.1% (54.8%; 82.0%)
	III	462	93.4% (90.8%; 96.2%)	82.6% (78.7%; 86.6%)	76.4% (71.9%; 81.1%)	73.3% (68.4%; 78.5%)	69.6% (64.2%; 75.5%)	59.5% (46.6%; 76.1%)
	IV	916	79.9% (77.3%; 82.7%)	66.0% (62.8%; 69.4%)	60.0% (56.6%; 63.6%)	56.2% (52.6%; 60.0%)	51.9% (48.1%; 56.0%)	36.0% (20.5%; 63.1%)
	X/NA	3,870	70.7% (69.2%; 72.2%)	60.9% (59.3%; 62.6%)	56.1% (54.4%; 57.9%)	51.3% (49.5%; 53.2%)	48.2% (46.3%; 50.2%)	36.4% (33.2%; 39.9%)
Lip (C00)	All	166	94.9% (90.2%; 99.9%)	88.6% (81.8%; 96.1%)	85.5% (77.1%; 94.9%)	82.2% (72.1%; 93.7%)	81.2% (69.5%; 94.9%)	76.3% (52.3%; 111.5%)
	I	94	99.4% (94.6%; 104.4%)	95.5% (87.5%; 104.2%)	91.2% (80.3%; 103.5%)	84.6% (71.0%; 100.8%)	86.0% (71.1%; 104.1%)	66.2% (33.6%; 130.4%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	8	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	31	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oral cavity (C02-C05.0, C06)	All	2,499	80.5% (78.9%; 82.2%)	70.7% (68.8%; 72.7%)	66.3% (64.2%; 68.5%)	62.5% (60.2%; 64.9%)	59.8% (57.3%; 62.4%)	49.3% (39.6%; 61.2%)
	I	660	96.4% (94.6%; 98.2%)	94.0% (91.6%; 96.4%)	91.5% (88.6%; 94.5%)	89.5% (86.1%; 93.0%)	86.7% (82.7%; 90.8%)	83.6% (76.4%; 91.5%)
	II	354	97.5% (95.0%; 99.9%)	90.4% (86.4%; 94.6%)	85.9% (80.6%; 91.5%)	81.9% (75.5%; 88.8%)	77.6% (70.1%; 85.9%)	66.5% (49.0%; 90.3%)
	III	265	92.1% (88.3%; 96.0%)	78.1% (72.7%; 83.9%)	73.5% (67.6%; 80.0%)	69.1% (62.6%; 76.3%)	66.2% (59.1%; 74.2%)	56.9% (43.0%; 75.4%)
	IV	581	80.8% (77.5%; 84.2%)	64.3% (60.2%; 68.6%)	57.4% (53.1%; 62.0%)	54.4% (49.9%; 59.3%)	51.0% (46.3%; 56.2%)	38.9% (18.8%; 80.6%)
	X/NA	681	52.1% (48.3%; 56.2%)	40.9% (37.1%; 45.1%)	36.7% (32.9%; 41.0%)	30.7% (26.8%; 35.1%)	29.4% (25.4%; 34.0%)	16.2% (10.1%; 26.0%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,688	77.0% (75.3%; 78.6%)	67.4% (65.5%; 69.2%)	61.9% (60.0%; 64.0%)	57.3% (55.2%; 59.4%)	53.6% (51.4%; 55.9%)	40.0% (36.1%; 44.2%)
	I	273	95.7% (93.0%; 98.5%)	93.6% (90.2%; 97.2%)	87.7% (83.1%; 92.5%)	84.6% (79.4%; 90.1%)	81.8% (76.0%; 88.1%)	55.0% (34.4%; 87.9%)
	II	109	94.2% (89.4%; 99.3%)	87.3% (80.5%; 94.7%)	82.3% (74.3%; 91.2%)	78.5% (69.6%; 88.4%)	75.6% (66.0%; 86.4%)	64.2% (48.4%; 85.2%)
	III	79	94.8% (89.4%; 100.4%)	86.9% (79.1%; 95.5%)	77.7% (68.0%; 88.7%)	75.4% (65.1%; 87.3%)	71.9% (61.1%; 84.7%)	78.0% (61.4%; 99.2%)
	IV	147	79.2% (72.7%; 86.2%)	65.7% (58.2%; 74.1%)	59.3% (51.5%; 68.3%)	52.9% (44.8%; 62.4%)	47.5% (39.2%; 57.6%)	27.9% (17.8%; 43.8%)
	X/NA	2,103	73.0% (71.1%; 75.0%)	62.4% (60.3%; 64.7%)	57.2% (55.0%; 59.6%)	52.2% (49.9%; 54.7%)	48.4% (46.0%; 51.0%)	36.1% (32.7%; 39.9%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	2,059	78.8% (77.0%; 80.7%)	68.8% (66.7%; 70.9%)	64.1% (61.9%; 66.4%)	60.0% (57.6%; 62.4%)	56.6% (54.2%; 59.3%)	41.3% (36.7%; 46.5%)
	I	249	95.5% (92.7%; 98.5%)	93.1% (89.5%; 96.9%)	86.9% (82.1%; 92.1%)	84.5% (79.1%; 90.3%)	81.4% (75.3%; 88.0%)	53.9% (33.1%; 88.0%)
	II	101	94.7% (89.8%; 99.8%)	88.1% (81.2%; 95.7%)	83.8% (75.6%; 92.9%)	79.6% (70.4%; 89.9%)	76.3% (66.4%; 87.7%)	64.6% (48.4%; 86.1%)
	III	70	93.9% (88.1%; 100.2%)	84.9% (76.4%; 94.4%)	79.2% (69.4%; 90.5%)	80.3% (70.3%; 91.7%)	76.5% (65.8%; 89.0%)	82.8% (65.6%; 104.5%)
	IV	103	84.6% (77.6%; 92.1%)	68.0% (59.3%; 78.0%)	64.0% (54.9%; 74.6%)	58.4% (48.8%; 69.8%)	55.9% (46.0%; 68.0%)	34.1% (21.4%; 54.3%)
	X/NA	1,550	74.1% (71.9%; 76.4%)	63.1% (60.6%; 65.6%)	58.5% (55.9%; 61.2%)	53.9% (51.1%; 56.7%)	50.3% (47.4%; 53.4%)	36.1% (32.0%; 40.7%)
Nasopharynx C11	All	190	85.2% (80.2%; 90.6%)	81.4% (75.8%; 87.5%)	77.7% (71.6%; 84.4%)	73.3% (66.4%; 80.8%)	72.0% (64.8%; 79.9%)	68.0% (59.1%; 78.2%)

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	4	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	5	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	175	84.5% (79.1%; 90.3%)	80.3% (74.3%; 86.7%)	79.0% (72.7%; 85.7%)	74.9% (67.8%; 82.6%)	74.4% (67.1%; 82.4%)	70.0% (60.7%; 80.7%)
Hypopharynx C12-C13	All	469	65.4% (61.1%; 69.9%)	55.3% (50.8%; 60.2%)	45.8% (41.2%; 50.9%)	37.4% (32.7%; 42.7%)	30.7% (26.1%; 36.1%)	21.8% (16.5%; 28.9%)
	I	22	N<50	N<50	N<50	N<50	N<50	N<50
	II	4	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50
	IV	39	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	397	63.0% (58.4%; 68.1%)	51.9% (47.0%; 57.3%)	42.2% (37.3%; 47.7%)	34.4% (29.6%; 40.1%)	28.1% (23.3%; 33.8%)	20.3% (14.9%; 27.7%)
Larynx (C32)	All	875	84.8% (82.3%; 87.3%)	77.7% (74.7%; 80.8%)	71.7% (68.3%; 75.2%)	67.5% (63.8%; 71.4%)	64.6% (60.6%; 68.7%)	50.6% (43.5%; 58.8%)
	I	151	96.6% (92.9%; 100.4%)	96.6% (92.2%; 101.2%)	95.3% (89.8%; 101.1%)	91.7% (84.5%; 99.5%)	91.7% (83.8%; 100.2%)	76.1% (57.0%; 101.6%)
	II	17	N<50	N<50	N<50	N<50	N<50	N<50
	III	31	N<50	N<50	N<50	N<50	N<50	N<50
	IV	61	77.9% (67.8%; 89.5%)	66.9% (55.6%; 80.4%)	59.7% (47.9%; 74.5%)	58.2% (45.9%; 73.7%)	53.0% (40.0%; 70.3%)	FU<10 y
	X/NA	615	81.4% (78.3%; 84.8%)	73.1% (69.4%; 76.9%)	66.3% (62.2%; 70.6%)	62.1% (57.7%; 66.8%)	59.1% (54.4%; 64.2%)	47.7% (40.3%; 56.5%)
Nasal cavity and paranasal sinuses (C30- C31)	All	383	79.9% (75.7%; 84.3%)	72.3% (67.4%; 77.5%)	68.4% (63.2%; 74.0%)	65.4% (59.8%; 71.4%)	63.1% (57.1%; 69.7%)	52.4% (42.0%; 65.4%)
	I	48	N<50	N<50	N<50	N<50	N<50	N<50
	II	23	N<50	N<50	N<50	N<50	N<50	N<50
	III	22	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	40	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	250	74.0% (68.4%; 80.0%)	65.7% (59.5%; 72.6%)	62.6% (56.1%; 69.9%)	59.7% (52.8%; 67.4%)	56.9% (49.7%; 65.2%)	38.9% (28.2%; 53.7%)
Salivary glands (C07-C08)	All	593	90.0% (87.2%; 92.8%)	88.1% (84.9%; 91.4%)	87.1% (83.5%; 90.9%)	85.3% (81.0%; 89.9%)	83.2% (78.3%; 88.4%)	66.0% (52.5%; 82.9%)
	I	166	100.6% (99.4%; 101.8%)	100.7% (98.5%; 102.9%)	100.0% (96.6%; 103.5%)	100.3% (96.0%; 104.8%)	103.4% (99.0%; 108.0%)	71.9% (42.1%; 122.9%)
	II	104	100.3% (97.3%; 103.3%)	100.3% (95.9%; 104.9%)	98.6% (92.4%; 105.3%)	98.5% (91.0%; 106.5%)	99.2% (90.4%; 109.0%)	83.0% (56.2%; 122.4%)
	III	59	92.3% (84.4%; 100.9%)	93.0% (84.2%; 102.7%)	91.9% (81.6%; 103.6%)	96.2% (85.3%; 108.4%)	89.1% (74.8%; 106.2%)	34.0% (10.4%; 111.0%)
	IV	81	80.5% (71.9%; 90.0%)	79.2% (70.0%; 89.5%)	75.8% (65.8%; 87.4%)	70.2% (59.2%; 83.2%)	66.1% (54.5%; 80.2%)	59.1% (43.3%; 80.7%)
	X/NA	183	78.0% (71.6%; 85.0%)	72.4% (65.1%; 80.6%)	72.4% (64.5%; 81.3%)	68.4% (59.2%; 79.0%)	63.8% (54.1%; 75.3%)	58.2% (43.6%; 77.6%)
Other and ill-defined sites (C14)	All	46	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	46	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,791	80.2% (79.7%; 80.7%)	70.3% (69.7%; 70.9%)	64.2% (63.5%; 64.9%)	59.9% (59.2%; 60.7%)	56.4% (55.7%; 57.2%)	43.2% (41.3%; 45.3%)
Males								
Head & Neck (C00-C14, C30- C32)	All	18,715	80.0% (79.4%; 80.6%)	69.6% (68.9%; 70.3%)	62.9% (62.1%; 63.7%)	58.5% (57.6%; 59.3%)	54.8% (53.9%; 55.8%)	41.4% (39.5%; 43.5%)
	I	4,227	96.4% (95.7%; 97.2%)	92.3% (91.2%; 93.4%)	88.4% (87.0%; 89.8%)	85.0% (83.2%; 86.7%)	82.1% (80.1%; 84.2%)	65.9% (59.6%; 72.9%)
	II	2,660	90.5% (89.2%; 91.8%)	83.0% (81.3%; 84.7%)	75.7% (73.7%; 77.7%)	71.2% (69.0%; 73.5%)	66.7% (64.3%; 69.3%)	52.9% (47.9%; 58.4%)
	III	2,956	82.7% (81.2%; 84.1%)	73.2% (71.5%; 75.0%)	67.1% (65.2%; 69.2%)	62.9% (60.7%; 65.1%)	59.0% (56.7%; 61.5%)	42.8% (38.6%; 47.5%)
	IV	42	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	6,933	71.5% (70.4%; 72.7%)	56.7% (55.5%; 58.0%)	47.9% (46.7%; 49.2%)	42.6% (41.3%; 43.9%)	38.2% (36.9%; 39.6%)	25.8% (23.8%; 28.0%)
	IVC	876	42.7% (39.4%; 46.1%)	23.0% (20.3%; 26.1%)	16.0% (13.5%; 18.8%)	12.5% (10.2%; 15.2%)	10.6% (8.4%; 13.3%)	7.9% (5.5%; 11.2%)
	X/NA	1,645	70.4% (68.1%; 72.8%)	58.7% (56.2%; 61.4%)	52.9% (50.3%; 55.7%)	47.8% (45.1%; 50.7%)	45.8% (42.9%; 48.9%)	34.6% (30.1%; 39.8%)
Lip (C00)	All	326	94.2% (90.7%; 97.7%)	90.1% (85.4%; 95.1%)	87.2% (81.5%; 93.3%)	86.9% (80.2%; 94.1%)	86.8% (79.2%; 95.2%)	89.5% (61.3%; 130.8%)
	I	201	98.6% (95.0%; 102.4%)	97.4% (92.1%; 103.1%)	96.2% (89.3%; 103.6%)	96.8% (88.4%; 105.9%)	96.4% (86.4%; 107.4%)	99.0% (58.7%; 167.0%)
	II	55	94.2% (86.4%; 102.9%)	91.5% (81.3%; 102.8%)	84.7% (72.0%; 99.6%)	88.2% (75.0%; 103.8%)	89.9% (75.6%; 107.0%)	104.9% (80.7%; 136.3%)
	III	22	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	14	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	3	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	31	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	All	4,314	80.5% (79.2%; 81.7%)	69.6% (68.2%; 71.1%)	62.4% (60.8%; 64.0%)	57.3% (55.6%; 59.1%)	53.2% (51.4%; 55.2%)	40.1% (36.7%; 43.8%)
	I	1,033	97.1% (95.8%; 98.5%)	92.0% (89.9%; 94.1%)	87.7% (85.1%; 90.3%)	83.2% (80.1%; 86.5%)	78.9% (75.2%; 82.8%)	59.6% (51.9%; 68.5%)
	II	665	90.0% (87.5%; 92.6%)	83.5% (80.3%; 86.8%)	75.0% (71.2%; 79.1%)	69.1% (64.7%; 73.7%)	62.6% (57.8%; 67.8%)	51.1% (43.1%; 60.6%)

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	658	82.6% (79.6%; 85.8%)	72.3% (68.6%; 76.1%)	65.1% (61.1%; 69.4%)	60.5% (56.2%; 65.2%)	57.7% (53.0%; 62.9%)	47.4% (38.6%; 58.2%)
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,720	70.9% (68.7%; 73.2%)	55.2% (52.8%; 57.7%)	46.2% (43.7%; 48.9%)	40.4% (37.8%; 43.1%)	36.3% (33.7%; 39.1%)	24.5% (20.5%; 29.2%)
	IVC	116	39.3% (31.2%; 49.5%)	22.1% (15.4%; 31.8%)	14.1% (8.4%; 23.8%)	12.9% (7.4%; 22.5%)	11.3% (6.1%; 21.0%)	FU<10 y
	X/NA	178	61.2% (54.2%; 69.1%)	47.4% (40.2%; 55.9%)	42.6% (35.4%; 51.4%)	37.4% (30.2%; 46.5%)	36.5% (29.0%; 45.9%)	27.1% (16.0%; 45.8%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,085	75.2% (74.2%; 76.2%)	62.7% (61.6%; 63.8%)	55.1% (53.9%; 56.3%)	50.3% (49.1%; 51.6%)	46.1% (44.8%; 47.4%)	32.8% (30.8%; 35.0%)
	I	1,111	93.2% (91.6%; 94.9%)	85.4% (83.0%; 87.8%)	79.1% (76.3%; 82.1%)	73.6% (70.3%; 77.0%)	70.3% (66.7%; 74.1%)	49.7% (42.5%; 58.2%)
	II	1,017	89.0% (86.9%; 91.1%)	79.6% (76.8%; 82.4%)	71.3% (68.1%; 74.7%)	67.0% (63.5%; 70.7%)	61.7% (57.9%; 65.8%)	45.8% (38.9%; 53.9%)
	III	1,354	81.2% (79.0%; 83.4%)	71.2% (68.6%; 73.8%)	66.0% (63.2%; 68.9%)	61.5% (58.5%; 64.7%)	57.4% (54.2%; 60.8%)	43.8% (38.9%; 49.3%)
	IV	41	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	3,652	70.7% (69.2%; 72.3%)	56.1% (54.4%; 57.8%)	46.8% (45.1%; 48.6%)	42.3% (40.6%; 44.2%)	37.8% (36.0%; 39.7%)	26.4% (23.9%; 29.2%)
	IVC	533	41.1% (37.1%; 45.6%)	20.8% (17.5%; 24.6%)	14.2% (11.4%; 17.7%)	10.7% (8.2%; 13.9%)	8.2% (5.9%; 11.4%)	5.9% (3.7%; 9.4%)
	X/NA	545	61.8% (57.8%; 66.2%)	48.6% (44.4%; 53.1%)	42.6% (38.4%; 47.2%)	36.2% (32.0%; 40.9%)	33.2% (29.0%; 38.0%)	17.8% (12.9%; 24.5%)
Oropharynx C01;C05.1- C05.9;C09-C10	All	5,386	77.7% (76.5%; 78.8%)	65.7% (64.3%; 67.0%)	58.7% (57.2%; 60.1%)	54.1% (52.5%; 55.6%)	49.8% (48.2%; 51.4%)	36.2% (33.6%; 39.0%)
	I	950	93.8% (92.0%; 95.6%)	86.2% (83.7%; 88.8%)	80.8% (77.8%; 84.0%)	75.4% (71.9%; 79.1%)	73.3% (69.4%; 77.3%)	51.8% (43.6%; 61.6%)
	II	748	91.1% (88.8%; 93.4%)	82.4% (79.3%; 85.6%)	73.8% (70.1%; 77.7%)	69.3% (65.2%; 73.6%)	64.5% (60.1%; 69.3%)	49.7% (41.6%; 59.4%)
	III	873	80.5% (77.7%; 83.3%)	70.9% (67.7%; 74.3%)	66.1% (62.7%; 69.8%)	62.2% (58.6%; 66.1%)	56.4% (52.4%; 60.6%)	43.6% (37.4%; 50.7%)
	IV	41	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,153	72.1% (70.2%; 74.1%)	57.7% (55.6%; 59.9%)	49.3% (47.1%; 51.7%)	45.2% (42.9%; 47.6%)	40.6% (38.3%; 43.1%)	29.6% (26.3%; 33.3%)
	IVC	275	43.9% (38.3%; 50.2%)	22.3% (17.8%; 28.1%)	17.2% (13.1%; 22.6%)	13.0% (9.4%; 18.1%)	10.8% (7.3%; 16.1%)	8.8% (5.2%; 14.8%)
	X/NA	400	63.5% (58.8%; 68.5%)	49.8% (44.9%; 55.2%)	43.1% (38.2%; 48.7%)	36.4% (31.5%; 42.0%)	34.2% (29.3%; 40.0%)	16.7% (11.2%; 24.9%)

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	All	465	85.0% (81.7%; 88.5%)	77.5% (73.6%; 81.7%)	72.2% (67.9%; 76.9%)	69.8% (65.2%; 74.8%)	67.3% (62.4%; 72.6%)	60.3% (53.3%; 68.1%)
	I	33	N<50	N<50	N<50	N<50	N<50	N<50
	II	87	92.1% (86.1%; 98.5%)	87.9% (80.1%; 96.4%)	87.0% (78.5%; 96.5%)	86.1% (76.9%; 96.3%)	87.2% (78.0%; 97.6%)	79.9% (62.9%; 101.4%)
	III	144	91.2% (86.4%; 96.3%)	88.5% (83.0%; 94.4%)	83.2% (76.5%; 90.5%)	80.4% (73.2%; 88.4%)	81.3% (74.0%; 89.4%)	78.2% (68.5%; 89.3%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	156	78.3% (71.9%; 85.2%)	70.0% (62.9%; 77.9%)	62.0% (54.3%; 70.7%)	57.9% (49.9%; 67.2%)	53.1% (44.7%; 63.1%)	44.3% (33.0%; 59.4%)
	IVC	13	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	32	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	All	2,381	67.4% (65.5%; 69.4%)	52.3% (50.2%; 54.4%)	42.7% (40.6%; 44.9%)	37.2% (35.1%; 39.5%)	32.8% (30.6%; 35.1%)	19.3% (16.4%; 22.7%)
	I	134	90.0% (84.6%; 95.8%)	79.9% (72.6%; 87.9%)	65.9% (57.2%; 76.0%)	58.0% (48.7%; 69.0%)	49.7% (40.2%; 61.5%)	34.0% (21.5%; 53.7%)
	II	185	78.6% (72.5%; 85.1%)	63.6% (56.5%; 71.6%)	53.1% (45.6%; 61.7%)	48.1% (40.3%; 57.3%)	38.4% (30.6%; 48.3%)	17.3% (8.3%; 36.0%)
	III	339	78.5% (74.0%; 83.2%)	64.3% (59.1%; 70.0%)	58.4% (52.7%; 64.6%)	51.5% (45.2%; 58.7%)	49.8% (43.3%; 57.3%)	29.8% (21.6%; 41.1%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,362	67.6% (65.1%; 70.2%)	51.8% (49.1%; 54.6%)	41.0% (38.2%; 43.9%)	35.8% (33.0%; 38.8%)	31.3% (28.6%; 34.4%)	18.7% (15.0%; 23.2%)
	IVC	247	37.0% (31.4%; 43.6%)	17.8% (13.6%; 23.4%)	10.3% (7.1%; 15.1%)	7.1% (4.3%; 11.6%)	4.4% (2.3%; 8.7%)	FU<10 y
	X/NA	117	54.8% (46.4%; 64.8%)	46.2% (37.8%; 56.5%)	41.6% (33.3%; 52.1%)	34.7% (26.6%; 45.4%)	30.7% (22.7%; 41.4%)	19.0% (10.3%; 34.9%)
Larynx (C32)	All	4,673	85.6% (84.5%; 86.7%)	78.5% (77.1%; 79.9%)	73.1% (71.5%; 74.7%)	68.6% (66.8%; 70.4%)	65.2% (63.3%; 67.2%)	48.2% (43.4%; 53.6%)
	I	1,720	97.6% (96.4%; 98.7%)	95.7% (94.1%; 97.4%)	92.6% (90.5%; 94.8%)	89.7% (86.9%; 92.6%)	87.3% (84.0%; 90.7%)	69.9% (59.2%; 82.6%)
	II	715	90.2% (87.7%; 92.7%)	82.8% (79.6%; 86.2%)	76.5% (72.7%; 80.5%)	71.3% (67.0%; 75.8%)	67.4% (62.7%; 72.5%)	54.5% (46.1%; 64.4%)
	III	703	82.4% (79.4%; 85.5%)	74.0% (70.4%; 77.7%)	67.9% (64.0%; 72.1%)	62.3% (58.0%; 66.9%)	58.2% (53.6%; 63.2%)	38.2% (30.4%; 47.9%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,074	73.4% (70.6%; 76.2%)	60.2% (57.2%; 63.5%)	52.6% (49.4%; 56.0%)	46.2% (42.9%; 49.8%)	41.3% (37.9%; 45.1%)	22.2% (17.5%; 28.3%)
	IVC	121	46.7% (38.4%; 56.7%)	24.6% (17.8%; 34.0%)	17.4% (11.4%; 26.6%)	15.3% (9.5%; 24.6%)	15.7% (9.8%; 25.3%)	11.8% (5.2%; 27.0%)

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	339	74.3% (69.5%; 79.5%)	68.3% (63.0%; 74.1%)	62.0% (56.1%; 68.4%)	57.6% (51.4%; 64.5%)	55.3% (48.6%; 62.9%)	37.6% (27.3%; 51.7%)
Nasal cavity and paranasal sinuses (C30- C31)	All	987	82.3% (79.7%; 84.9%)	70.2% (67.1%; 73.6%)	64.3% (60.7%; 68.0%)	60.5% (56.7%; 64.6%)	60.2% (56.2%; 64.5%)	48.0% (39.4%; 58.5%)
	I	122	96.6% (92.2%; 101.2%)	91.6% (84.9%; 98.8%)	86.1% (77.6%; 95.6%)	82.6% (73.1%; 93.5%)	85.7% (75.8%; 96.9%)	78.1% (57.6%; 105.9%)
	II	111	100.4% (96.8%; 104.1%)	95.0% (88.3%; 102.1%)	88.5% (79.4%; 98.8%)	88.2% (77.6%; 100.3%)	88.9% (77.1%; 102.6%)	62.1% (31.6%; 121.9%)
	III	120	90.4% (84.2%; 97.0%)	83.5% (75.5%; 92.4%)	74.5% (64.4%; 86.2%)	73.3% (62.5%; 85.9%)	76.7% (65.4%; 89.9%)	40.1% (18.0%; 89.3%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	310	71.7% (66.6%; 77.2%)	56.5% (50.7%; 62.8%)	51.6% (45.7%; 58.3%)	46.8% (40.5%; 54.1%)	44.7% (38.1%; 52.3%)	28.3% (18.0%; 44.4%)
	IVC	42	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	284	82.8% (78.2%; 87.8%)	68.0% (62.2%; 74.3%)	62.5% (56.1%; 69.5%)	57.5% (50.8%; 65.2%)	56.0% (48.9%; 64.0%)	57.3% (47.6%; 68.9%)
Salivary glands (C07-C08)	All	762	87.1% (84.4%; 89.9%)	76.1% (72.5%; 79.8%)	70.4% (66.4%; 74.7%)	68.1% (63.6%; 72.8%)	63.5% (57.9%; 69.6%)	57.1% (48.6%; 67.2%)
	I	115	100.7% (98.1%; 103.3%)	100.3% (96.0%; 104.7%)	99.9% (94.2%; 105.9%)	102.7% (96.5%; 109.2%)	93.8% (80.8%; 108.8%)	93.7% (76.1%; 115.3%)
	II	118	97.9% (93.7%; 102.2%)	92.9% (86.3%; 100.0%)	91.8% (84.3%; 100.0%)	91.9% (83.3%; 101.4%)	91.2% (81.1%; 102.6%)	73.4% (49.8%; 108.2%)
	III	112	92.7% (86.4%; 99.4%)	83.6% (74.7%; 93.6%)	75.4% (64.1%; 88.8%)	80.2% (67.5%; 95.2%)	69.0% (50.8%; 93.7%)	40.6% (20.1%; 81.7%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	202	80.1% (74.1%; 86.6%)	60.4% (53.2%; 68.7%)	52.5% (44.7%; 61.5%)	40.4% (32.5%; 50.2%)	35.4% (27.2%; 46.2%)	33.8% (23.1%; 49.4%)
	IVC	63	50.7% (39.3%; 65.4%)	37.5% (26.7%; 52.8%)	28.9% (18.6%; 44.9%)	20.5% (11.1%; 37.8%)	18.7% (9.6%; 36.3%)	11.6% (4.1%; 32.5%)
	X/NA	152	88.8% (83.1%; 94.9%)	75.8% (68.3%; 84.1%)	68.5% (60.1%; 78.0%)	68.8% (60.0%; 78.9%)	68.3% (58.9%; 79.3%)	71.1% (56.1%; 90.2%)
Other and ill- defined sites (C14)	All	138	53.5% (45.6%; 62.7%)	42.8% (35.0%; 52.3%)	38.0% (30.3%; 47.5%)	31.6% (24.2%; 41.1%)	30.1% (22.7%; 39.9%)	13.6% (6.4%; 28.9%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	137	53.1% (45.3%; 62.4%)	42.3% (34.6%; 51.8%)	37.4% (29.8%; 47.0%)	31.0% (23.6%; 40.5%)	29.4% (22.1%; 39.2%)	13.9% (6.6%; 29.4%)
Females								
Head & Neck (C00-C14, C30- C32)	All	7,076	80.6% (79.7%; 81.6%)	72.3% (71.1%; 73.4%)	67.6% (66.4%; 68.9%)	63.8% (62.5%; 65.2%)	60.8% (59.3%; 62.2%)	48.3% (43.7%; 53.4%)
	I	1,799	96.3% (95.2%; 97.4%)	94.1% (92.6%; 95.5%)	91.0% (89.1%; 92.9%)	88.2% (85.9%; 90.4%)	86.9% (84.4%; 89.5%)	77.4% (70.2%; 85.4%)
	II	1,142	92.7% (91.0%; 94.5%)	85.7% (83.3%; 88.2%)	81.2% (78.4%; 84.2%)	76.8% (73.5%; 80.2%)	74.0% (70.3%; 77.9%)	59.8% (51.7%; 69.0%)
	III	1,064	83.1% (80.7%; 85.6%)	73.3% (70.4%; 76.3%)	67.0% (63.9%; 70.3%)	63.2% (59.9%; 66.8%)	58.9% (55.2%; 62.8%)	48.4% (40.7%; 57.4%)
	IV	14	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,383	68.4% (66.5%; 70.4%)	55.5% (53.4%; 57.6%)	49.5% (47.3%; 51.7%)	45.2% (43.0%; 47.5%)	41.6% (39.3%; 44.0%)	27.6% (19.7%; 38.7%)
	IVC	227	35.1% (29.3%; 42.1%)	22.5% (17.6%; 28.9%)	16.2% (11.8%; 22.3%)	14.8% (10.4%; 21.0%)	12.6% (8.5%; 18.7%)	FU<10 y
	X/NA	662	72.9% (69.4%; 76.6%)	65.0% (61.2%; 69.1%)	62.2% (58.1%; 66.4%)	55.5% (51.1%; 60.2%)	51.7% (47.2%; 56.7%)	39.1% (33.2%; 46.1%)
Lip (C00)	All	166	94.9% (90.2%; 99.9%)	88.6% (81.8%; 96.1%)	85.5% (77.1%; 94.9%)	82.2% (72.1%; 93.7%)	81.2% (69.5%; 94.9%)	76.3% (52.3%; 111.5%)
	I	103	98.7% (93.9%; 103.7%)	95.3% (87.7%; 103.5%)	90.6% (80.3%; 102.2%)	83.3% (70.5%; 98.5%)	85.0% (70.9%; 101.7%)	66.4% (36.2%; 121.8%)
	II	27	N<50	N<50	N<50	N<50	N<50	N<50
	III	9	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	13	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	14	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	All	2,499	80.5% (78.9%; 82.2%)	70.7% (68.8%; 72.7%)	66.3% (64.2%; 68.5%)	62.5% (60.2%; 64.9%)	59.8% (57.3%; 62.4%)	49.3% (39.6%; 61.2%)
	I	704	96.3% (94.6%; 98.1%)	93.5% (91.1%; 95.9%)	90.7% (87.7%; 93.8%)	87.9% (84.4%; 91.5%)	84.9% (80.9%; 89.0%)	82.0% (75.1%; 89.5%)
	II	419	92.7% (89.6%; 95.8%)	85.8% (81.7%; 90.1%)	80.4% (75.3%; 85.9%)	76.2% (70.1%; 82.8%)	72.6% (65.7%; 80.2%)	61.2% (45.6%; 82.0%)

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	331	84.8% (80.6%; 89.2%)	70.8% (65.6%; 76.5%)	66.1% (60.4%; 72.2%)	60.6% (54.5%; 67.4%)	58.2% (51.6%; 65.6%)	50.0% (38.1%; 65.5%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	923	65.8% (62.7%; 69.0%)	51.3% (48.0%; 54.9%)	45.7% (42.3%; 49.4%)	42.4% (38.9%; 46.3%)	40.2% (36.5%; 44.2%)	26.6% (13.6%; 52.0%)
	IVC	46	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	117	62.5% (53.9%; 72.4%)	53.6% (44.7%; 64.4%)	49.9% (40.7%; 61.1%)	42.5% (33.4%; 54.1%)	40.0% (30.7%; 52.1%)	22.2% (12.5%; 39.3%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,688	77.0% (75.3%; 78.6%)	67.4% (65.5%; 69.2%)	61.9% (60.0%; 64.0%)	57.3% (55.2%; 59.4%)	53.6% (51.4%; 55.9%)	40.0% (36.1%; 44.2%)
	I	468	93.8% (91.4%; 96.3%)	90.5% (87.5%; 93.7%)	85.7% (81.9%; 89.6%)	82.1% (77.8%; 86.7%)	80.1% (75.4%; 85.2%)	57.3% (39.7%; 82.7%)
	II	413	90.6% (87.6%; 93.7%)	82.2% (78.2%; 86.3%)	78.8% (74.4%; 83.4%)	72.7% (67.7%; 78.0%)	69.9% (64.6%; 75.7%)	56.0% (47.4%; 66.1%)
	III	462	79.4% (75.6%; 83.3%)	70.9% (66.7%; 75.5%)	64.7% (60.1%; 69.6%)	61.3% (56.5%; 66.6%)	57.3% (52.1%; 63.0%)	48.2% (40.0%; 58.2%)
	IV	14	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,056	69.9% (67.2%; 72.8%)	57.1% (54.1%; 60.3%)	50.0% (46.9%; 53.3%)	45.1% (41.9%; 48.5%)	40.5% (37.2%; 44.0%)	28.6% (24.2%; 33.6%)
	IVC	110	28.5% (21.2%; 38.3%)	18.6% (12.6%; 27.5%)	12.4% (7.5%; 20.6%)	11.3% (6.6%; 19.5%)	9.0% (4.8%; 16.9%)	FU<10 y
	X/NA	206	69.9% (63.7%; 76.7%)	58.8% (52.2%; 66.3%)	57.1% (50.3%; 64.8%)	47.9% (40.7%; 56.3%)	44.6% (37.4%; 53.2%)	28.6% (21.1%; 38.6%)
Oropharynx C01;C05.1- C05.9;C09-C10	All	2,059	78.8% (77.0%; 80.7%)	68.8% (66.7%; 70.9%)	64.1% (61.9%; 66.4%)	60.0% (57.6%; 62.4%)	56.6% (54.2%; 59.3%)	41.3% (36.7%; 46.5%)
	I	412	94.5% (92.1%; 97.1%)	90.6% (87.4%; 94.0%)	86.1% (82.1%; 90.3%)	83.4% (78.9%; 88.1%)	81.4% (76.4%; 86.8%)	57.0% (38.5%; 84.4%)
	II	313	91.1% (87.8%; 94.7%)	82.1% (77.5%; 86.9%)	78.8% (73.7%; 84.2%)	72.9% (67.2%; 79.1%)	70.7% (64.6%; 77.4%)	51.8% (41.7%; 64.4%)
	III	335	80.1% (75.7%; 84.7%)	71.2% (66.2%; 76.6%)	67.8% (62.5%; 73.6%)	65.5% (59.9%; 71.6%)	60.8% (54.8%; 67.5%)	51.1% (40.8%; 63.9%)
	IV	14	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	762	71.8% (68.6%; 75.2%)	58.7% (55.2%; 62.4%)	51.7% (48.1%; 55.6%)	47.0% (43.3%; 51.1%)	43.2% (39.4%; 47.3%)	30.6% (25.5%; 36.7%)
	IVC	73	31.9% (22.8%; 44.5%)	16.8% (10.1%; 28.0%)	10.4% (5.3%; 20.6%)	10.6% (5.3%; 20.9%)	7.2% (3.1%; 16.8%)	FU<10 y
	X/NA	168	70.0% (63.1%; 77.6%)	58.6% (51.3%; 66.9%)	57.5% (50.0%; 66.0%)	51.4% (43.5%; 60.8%)	48.8% (40.8%; 58.4%)	31.6% (23.0%; 43.4%)

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	All	190	85.2% (80.2%; 90.6%)	81.4% (75.8%; 87.5%)	77.7% (71.6%; 84.4%)	73.3% (66.4%; 80.8%)	72.0% (64.8%; 79.9%)	68.0% (59.1%; 78.2%)
	I	14	N<50	N<50	N<50	N<50	N<50	N<50
	II	48	N<50	N<50	N<50	N<50	N<50	N<50
	III	52	84.7% (75.2%; 95.5%)	79.1% (68.4%; 91.4%)	74.7% (63.2%; 88.3%)	75.0% (63.5%; 88.7%)	71.8% (59.1%; 87.1%)	73.9% (60.9%; 89.7%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	58	76.3% (65.9%; 88.3%)	71.5% (60.5%; 84.5%)	72.0% (60.9%; 85.1%)	72.7% (61.5%; 85.9%)	70.2% (58.2%; 84.7%)	58.0% (41.0%; 82.2%)
	IVC	6	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	12	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	All	469	65.4% (61.1%; 69.9%)	55.3% (50.8%; 60.2%)	45.8% (41.2%; 50.9%)	37.4% (32.7%; 42.7%)	30.7% (26.1%; 36.1%)	21.8% (16.5%; 28.9%)
	I	44	N<50	N<50	N<50	N<50	N<50	N<50
	II	54	80.6% (70.2%; 92.5%)	67.8% (55.8%; 82.3%)	66.6% (54.3%; 81.6%)	59.4% (46.5%; 76.0%)	50.0% (36.3%; 68.8%)	45.7% (29.7%; 70.4%)
	III	75	72.7% (63.1%; 83.8%)	64.2% (53.8%; 76.6%)	44.3% (33.8%; 58.0%)	33.9% (23.8%; 48.3%)	32.5% (22.3%; 47.4%)	18.9% (8.6%; 41.4%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	239	62.3% (56.3%; 68.8%)	48.8% (42.6%; 55.9%)	39.1% (32.9%; 46.3%)	32.0% (26.0%; 39.4%)	23.5% (17.8%; 31.0%)	14.6% (9.0%; 23.5%)
	IVC	31	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	26	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	All	875	84.8% (82.3%; 87.3%)	77.7% (74.7%; 80.8%)	71.7% (68.3%; 75.2%)	67.5% (63.8%; 71.4%)	64.6% (60.6%; 68.7%)	50.6% (43.5%; 58.8%)
	I	302	96.2% (93.4%; 99.0%)	94.6% (91.1%; 98.3%)	92.3% (87.9%; 96.9%)	89.7% (84.3%; 95.3%)	90.9% (85.2%; 97.0%)	82.2% (67.9%; 99.5%)
	II	140	89.7% (84.5%; 95.2%)	81.2% (74.5%; 88.4%)	73.6% (66.0%; 82.2%)	67.7% (59.4%; 77.3%)	64.1% (55.2%; 74.4%)	49.2% (36.9%; 65.6%)
	III	159	85.0% (79.2%; 91.2%)	75.2% (68.2%; 82.9%)	66.5% (58.7%; 75.4%)	61.6% (53.2%; 71.5%)	52.2% (42.9%; 63.6%)	36.5% (22.1%; 60.4%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	189	69.5% (63.1%; 76.6%)	56.4% (49.6%; 64.3%)	49.4% (42.3%; 57.6%)	44.6% (37.4%; 53.2%)	42.5% (35.1%; 51.4%)	18.2% (9.4%; 35.2%)
	IVC	24	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	61	76.9% (66.7%; 88.7%)	73.5% (62.5%; 86.4%)	66.9% (55.1%; 81.2%)	60.9% (47.8%; 77.7%)	51.7% (38.5%; 69.5%)	41.8% (27.2%; 64.2%)
Nasal cavity and paranasal sinuses (C30-C31)	All	383	79.9% (75.7%; 84.3%)	72.3% (67.4%; 77.5%)	68.4% (63.2%; 74.0%)	65.4% (59.8%; 71.4%)	63.1% (57.1%; 69.7%)	52.4% (42.0%; 65.4%)
	I	65	96.8% (91.8%; 102.1%)	98.5% (93.4%; 103.9%)	97.7% (90.8%; 105.1%)	97.3% (89.3%; 106.0%)	99.2% (91.0%; 108.0%)	89.7% (72.4%; 111.2%)
	II	31	N<50	N<50	N<50	N<50	N<50	N<50
	III	34	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	105	60.7% (51.7%; 71.3%)	49.2% (39.8%; 60.8%)	46.8% (37.4%; 58.7%)	40.7% (31.1%; 53.2%)	40.0% (30.1%; 53.1%)	22.6% (10.2%; 50.2%)
	IVC	16	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	132	84.4% (77.9%; 91.5%)	75.0% (67.2%; 83.8%)	73.8% (65.6%; 83.1%)	70.4% (61.6%; 80.4%)	64.6% (55.0%; 75.8%)	43.0% (29.9%; 61.8%)
Salivary glands (C07-C08)	All	593	90.0% (87.2%; 92.8%)	88.1% (84.9%; 91.4%)	87.1% (83.5%; 90.9%)	85.3% (81.0%; 89.9%)	83.2% (78.3%; 88.4%)	66.0% (52.5%; 82.9%)
	I	173	100.6% (99.5%; 101.8%)	100.8% (98.7%; 102.9%)	100.2% (97.0%; 103.6%)	100.7% (96.6%; 104.9%)	102.1% (97.0%; 107.5%)	77.5% (48.9%; 122.7%)
	II	119	99.9% (96.8%; 103.0%)	100.4% (96.2%; 104.8%)	99.8% (94.1%; 105.9%)	99.7% (92.7%; 107.3%)	101.1% (92.6%; 110.5%)	76.4% (51.0%; 114.5%)
	III	74	89.3% (81.5%; 97.9%)	89.1% (80.2%; 98.9%)	88.4% (78.1%; 100.1%)	89.2% (77.4%; 102.8%)	80.2% (66.3%; 96.9%)	47.7% (20.0%; 113.5%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	108	80.7% (73.0%; 89.2%)	74.6% (65.5%; 84.9%)	74.0% (64.3%; 85.2%)	68.5% (57.6%; 81.4%)	63.7% (52.1%; 77.9%)	53.8% (39.4%; 73.5%)
	IVC	31	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	89	86.8% (79.2%; 95.2%)	85.9% (77.4%; 95.5%)	83.5% (73.7%; 94.6%)	78.3% (65.9%; 93.1%)	74.6% (61.5%; 90.5%)	74.7% (55.8%; 100.1%)
Other and ill-defined sites (C14)	All	46	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2014-2023								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	46	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

5. CANCER SURVIVAL TRENDS



5.1. Head & Neck cancer survival trends: by tumour stage

5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	All	9341	78.1% (77.2%; 79.0%)	58.3% (57.2%; 59.4%)	49.5% (48.4%; 50.7%)	2737	80.1% (78.5%; 81.7%)	63.1% (61.1%; 65.1%)	55.6% (53.5%; 57.8%)
	I	1344	97.6% (96.4%; 98.8%)	89.7% (87.4%; 92.0%)	81.6% (78.6%; 84.7%)	412	96.3% (94.1%; 98.6%)	84.5% (80.4%; 88.9%)	77.1% (72.2%; 82.3%)
	II	978	91.5% (89.6%; 93.6%)	71.3% (68.1%; 74.6%)	61.3% (57.8%; 65.1%)	323	88.4% (84.7%; 92.3%)	73.7% (68.6%; 79.2%)	65.0% (59.0%; 71.6%)
	III	1224	83.9% (81.7%; 86.1%)	62.2% (59.3%; 65.2%)	51.6% (48.5%; 54.9%)	320	82.0% (77.6%; 86.6%)	63.1% (57.7%; 69.1%)	56.9% (51.1%; 63.3%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	2926	69.7% (68.0%; 71.4%)	43.3% (41.4%; 45.2%)	34.1% (32.3%; 36.0%)	729	72.4% (69.1%; 75.8%)	48.6% (44.9%; 52.5%)	39.5% (35.9%; 43.5%)
	IVC	335	44.9% (39.8%; 50.7%)	12.9% (9.7%; 17.2%)	7.7% (5.2%; 11.4%)	61	53.1% (41.9%; 67.2%)	27.1% (17.9%; 40.9%)	20.9% (12.7%; 34.2%)
	X/NA	2582	73.3% (71.5%; 75.1%)	57.3% (55.3%; 59.5%)	49.2% (47.0%; 51.6%)	905	76.5% (73.7%; 79.5%)	63.5% (60.0%; 67.1%)	57.1% (53.4%; 61.1%)
2009-2013	All	9609	79.0% (78.1%; 79.8%)	60.3% (59.2%; 61.4%)	51.8% (50.6%; 53.0%)	3201	81.6% (80.2%; 83.1%)	66.3% (64.5%; 68.2%)	59.3% (57.3%; 61.3%)
	I	1813	96.3% (95.1%; 97.4%)	88.8% (86.8%; 90.9%)	83.3% (80.8%; 86.0%)	688	96.5% (94.8%; 98.2%)	89.5% (86.6%; 92.5%)	85.7% (82.1%; 89.4%)
	II	1160	87.5% (85.4%; 89.7%)	72.8% (69.8%; 75.8%)	63.5% (60.2%; 67.0%)	409	90.6% (87.5%; 93.8%)	79.3% (74.8%; 84.0%)	71.7% (66.6%; 77.3%)
	III	1359	81.2% (79.0%; 83.4%)	60.4% (57.6%; 63.3%)	50.7% (47.8%; 53.8%)	416	86.8% (83.3%; 90.4%)	69.8% (65.1%; 74.9%)	57.0% (51.7%; 62.9%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	3450	72.0% (70.5%; 73.6%)	46.4% (44.7%; 48.2%)	36.3% (34.6%; 38.1%)	1018	73.0% (70.3%; 75.9%)	50.7% (47.5%; 54.1%)	43.1% (39.9%; 46.6%)
	IVC	385	44.8% (40.0%; 50.1%)	19.9% (16.1%; 24.6%)	10.6% (7.7%; 14.5%)	101	47.6% (38.7%; 58.6%)	25.8% (17.7%; 37.8%)	21.8% (14.3%; 33.2%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	X/NA	1552	74.1% (71.8%; 76.4%)	56.9% (54.2%; 59.7%)	49.9% (47.0%; 53.0%)	599	75.5% (71.9%; 79.3%)	61.2% (56.9%; 65.9%)	54.6% (49.9%; 59.8%)
2014-2018	All	9666	79.0% (78.1%; 79.8%)	60.8% (59.7%; 61.9%)	52.7% (51.5%; 53.9%)	3494	79.1% (77.6%; 80.5%)	65.3% (63.6%; 67.1%)	58.3% (56.4%; 60.2%)
	I	1974	96.0% (94.9%; 97.2%)	87.7% (85.7%; 89.7%)	81.2% (78.5%; 83.9%)	776	95.9% (94.1%; 97.6%)	89.0% (86.1%; 91.9%)	83.2% (79.7%; 86.9%)
	II	1251	89.9% (88.0%; 91.8%)	74.2% (71.5%; 77.1%)	65.5% (62.3%; 68.9%)	523	89.9% (87.1%; 92.9%)	79.5% (75.4%; 83.8%)	73.4% (68.6%; 78.4%)
	III	1432	81.5% (79.4%; 83.7%)	65.3% (62.6%; 68.2%)	56.7% (53.6%; 60.0%)	495	84.3% (81.0%; 87.9%)	68.0% (63.6%; 72.8%)	59.9% (55.0%; 65.2%)
	IV	1	N<50	N<50	N<50	1	N<50	N<50	N<50
	IVA-B	3696	71.9% (70.4%; 73.4%)	47.3% (45.6%; 49.1%)	37.8% (36.2%; 39.6%)	1237	67.4% (64.8%; 70.2%)	48.4% (45.5%; 51.4%)	41.2% (38.2%; 44.3%)
	IVC	448	40.9% (36.5%; 45.8%)	14.0% (11.0%; 17.8%)	9.7% (7.1%; 13.4%)	108	32.8% (25.0%; 43.1%)	15.1% (9.6%; 23.6%)	12.4% (7.5%; 20.6%)
	X/NA	1066	71.0% (68.2%; 74.0%)	52.7% (49.4%; 56.1%)	45.4% (42.0%; 49.1%)	413	73.7% (69.3%; 78.3%)	63.3% (58.2%; 68.7%)	51.0% (45.6%; 57.1%)
2019-2023	All	9335	80.9% (80.0%; 81.7%)	64.8% (63.7%; 66.0%)	56.6% (55.1%; 58.1%)	3678	82.1% (80.8%; 83.5%)	69.6% (67.8%; 71.4%)	63.0% (60.6%; 65.5%)
	I	2285	96.8% (95.8%; 97.8%)	88.8% (86.9%; 90.8%)	82.8% (79.6%; 86.0%)	1034	96.6% (95.2%; 98.0%)	92.4% (90.0%; 94.9%)	90.8% (87.3%; 94.4%)
	II	1423	91.0% (89.3%; 92.8%)	76.9% (74.1%; 79.8%)	67.3% (63.1%; 71.7%)	622	94.9% (92.8%; 97.1%)	82.7% (78.8%; 86.8%)	72.8% (65.9%; 80.4%)
	III	1533	83.6% (81.6%; 85.6%)	68.6% (65.9%; 71.5%)	61.8% (58.2%; 65.6%)	571	82.1% (78.7%; 85.5%)	66.2% (61.8%; 70.9%)	57.0% (50.9%; 63.9%)
	IV	41	N<50	N<50	N<50	13	N<50	N<50	N<50
	IVA-B	3260	71.0% (69.4%; 72.6%)	48.5% (46.6%; 50.5%)	37.9% (35.6%; 40.3%)	1150	69.4% (66.7%; 72.3%)	50.7% (47.6%; 54.1%)	41.6% (37.8%; 45.9%)
	IVC	428	44.5% (39.9%; 49.6%)	18.3% (14.6%; 22.9%)	11.2% (7.9%; 15.9%)	119	37.2% (29.3%; 47.3%)	17.2% (10.9%; 27.1%)	11.3% (5.3%; 24.1%)
	X/NA	583	69.0% (65.2%; 73.0%)	53.6% (49.1%; 58.4%)	46.3% (41.2%; 52.1%)	250	71.7% (66.1%; 77.8%)	59.7% (53.2%; 67.0%)	54.2% (46.6%; 63.1%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Head & Neck cancer mortality: by region

6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	1	0	1	0	0	4	11	26	51	78	98	84	61	41	30	17	3	506	9.6
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[0.0]	[0.0]	[1.1]	[2.9]	[6.5]	[12.6]	[21.5]	[32.0]	[31.7]	[35.0]	[31.4]	[38.6]	[60.6]	[55.0]	[8.9]	(8.7; 10.4)
Brussels	0	0	0	0	0	0	0	0	0	1	2	4	6	2	6	3	7	3	3	0	37	10.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[11.7]	[22.0]	[9.6]	[35.9]	[26.1]	[82.8]	[59.4]	[137.9]	[0.0]	[6.2]	(6.7; 13.3)
Flanders	0	0	0	1	0	0	0	0	2	6	14	30	49	64	53	39	31	19	11	1	320	9.7
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.8]	[6.0]	[12.3]	[22.2]	[34.1]	[32.7]	[34.2]	[35.9]	[36.8]	[60.0]	[27.9]	[9.7]	(8.6; 10.8)
Wallonia	0	0	0	0	0	1	0	0	2	4	10	17	23	32	25	19	3	8	3	2	149	9.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[3.2]	[8.1]	[13.6]	[20.0]	[32.7]	[28.9]	[39.2]	[8.3]	[38.2]	[39.6]	[142.2]	[8.3]	(7.7; 10.8)
Females																						
Belgium	0	0	0	0	0	0	0	0	0	3	7	14	18	29	33	24	22	15	5	3	173	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.8]	[3.5]	[4.8]	[8.9]	[11.1]	[11.3]	[11.9]	[11.1]	[7.5]	[15.6]	[3.0]	(2.3; 3.2)
Brussels	0	0	0	0	0	0	0	0	0	0	2	1	2	2	2	3	2	2	1	0	17	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.4]	[3.0]	[6.7]	[8.2]	[9.3]	[18.5]	[14.6]	[19.7]	[17.4]	[0.0]	[2.7]	(1.8; 5.1)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	0	0	0	2	3	10	11	22	21	14	15	6	3	3	110	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[1.3]	[4.2]	[5.0]	[11.4]	[12.1]	[10.5]	[12.9]	[7.1]	[7.5]	[26.7]	[3.3]	(2.4; 3.5)
Wallonia	0	0	0	0	0	0	0	0	0	1	2	3	5	5	10	7	5	7	1	0	46	2.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.6]	[2.4]	[4.1]	[4.6]	[9.9]	[11.0]	[9.1]	[17.5]	[4.9]	[0.0]	[2.5]	(1.6; 3.0)

7. CANCER MORTALITY TRENDS



7.1. Head & Neck cancer mortality trends: by region

7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	601	636	620	569	594	616	585	572	624	642	626	600	603	565	539	544	552	506		
	CR	11.8	12.4	12.1	11.0	11.4	11.7	11.0	10.7	11.5	11.8	11.4	10.9	10.9	10.1	9.6	9.7	9.8	8.9		
	ESR2013	14.5	14.9	14.3	13.0	13.2	13.5	13.0	12.3	13.3	13.8	12.8	12.2	12.3	11.1	10.5	10.6	10.5	9.6	-2.4 (-2.9; -1.9)	2004-2021
																				-1.6 (-2.2; -1.0)	2004-2020
																				-4.8 (-7.0; -2.6)	2018-2021
Brussels	N	60	52	61	61	56	58	49	53	65	54	55	53	53	53	49	53	38	37		
	CR	12.5	10.8	12.5	12.3	11.1	11.2	9.3	9.8	11.8	9.6	9.7	9.3	9.1	9.1	8.4	8.9	6.4	6.2		
	ESR2013	17.7	15.9	17.9	17.6	16.0	16.0	13.9	15.5	17.5	15.7	15.1	14.9	15.6	13.7	13.4	13.8	10.0	10.0	-2.8 (-3.6; -2.0)	2004-2021
																				-0.8 (-2.1; 0.5)	2004-2020
																				-6.4 (-8.8; -3.9)	2016-2021
Flanders	N	365	353	350	328	319	343	350	341	348	372	384	391	376	348	327	328	343	320		
	CR	12.3	11.8	11.7	10.9	10.5	11.2	11.3	11.0	11.1	11.8	12.1	12.3	11.7	10.8	10.1	10.1	10.5	9.7		
	ESR2013	14.9	13.6	13.5	12.5	11.7	12.6	12.7	11.9	12.3	13.0	12.8	12.8	12.3	11.2	10.2	10.4	10.5	9.7	-1.7 (-2.3; -1.1)	2004-2021
Wallonia	N	176	231	209	180	219	215	186	178	211	216	187	156	174	164	163	163	171	149		
	CR	10.7	14.0	12.6	10.8	13.1	12.7	10.9	10.4	12.2	12.5	10.7	8.9	9.9	9.3	9.2	9.2	9.6	8.3		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
ESR2013	12.9	16.7	15.0	13.0	15.4	14.7	13.2	12.4	14.2	14.7	12.3	10.0	11.3	10.5	10.4	10.4	10.7	9.2	-2.7 (-3.6; -1.7)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	176	155	150	154	164	163	169	171	183	191	177	203	191	222	172	194	151	173		
	CR	3.3	2.9	2.8	2.9	3.0	3.0	3.1	3.1	3.3	3.4	3.1	3.6	3.3	3.9	3.0	3.3	2.6	3.0		
	ESR2013	3.4	3.0	2.9	2.9	3.0	2.9	3.1	3.1	3.3	3.4	3.1	3.4	3.2	3.7	2.7	3.1	2.4	2.8		
																				-1.0 (-1.8; -0.1)	2004-2021
Brussels	N	29	23	21	20	15	18	17	18	20	14	15	19	28	27	12	16	13	17		
	CR	5.6	4.4	4.0	3.7	2.8	3.3	3.0	3.1	3.4	2.4	2.5	3.2	4.6	4.4	2.0	2.6	2.1	2.7		
	ESR2013	6.2	4.5	4.8	4.3	2.9	3.9	3.1	3.6	4.4	2.9	3.1	4.0	5.9	5.8	2.4	3.3	2.6	3.4		
																				-2.0 (-4.5; 0.5)	2004-2021
Flanders	N	78	81	68	85	87	86	89	87	98	112	94	114	115	121	103	108	104	110		
	CR	2.6	2.6	2.2	2.7	2.8	2.7	2.8	2.7	3.0	3.5	2.9	3.5	3.5	3.7	3.1	3.2	3.1	3.3		
	ESR2013	2.6	2.6	2.2	2.7	2.7	2.6	2.8	2.7	3.0	3.3	2.8	3.2	3.2	3.3	2.7	2.9	2.7	2.9		
																				0.7 (-0.1; 1.4)	2004-2021
Wallonia	N	69	51	61	49	62	59	63	66	65	65	68	70	48	74	57	70	34	46		
	CR	4.0	2.9	3.5	2.8	3.5	3.3	3.5	3.6	3.6	3.6	3.7	3.8	2.6	4.0	3.1	3.8	1.8	2.5		
	ESR2013	4.1	3.1	3.6	2.9	3.6	3.3	3.4	3.7	3.5	3.7	3.6	3.7	2.5	3.9	2.9	3.5	1.7	2.3		
																				-2.5 (-4.2; -0.9)	2004-2021
																				0.4 (-2.3; 3.2)	2004-2015
																				-7.7 (-12.7; -2.5)	2016-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025